UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended March 31, ~~2021~~2022


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-16751

ANTHEM, INC.

(Exact name of registrant as specified in its charter)


Indiana						35-2145715
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification Number)

220 Virginia Avenue

Indianapolis, Indiana 46204

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (800) 331-1476

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value

ANTM

New York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April ~~15, 2021, 244,840,654~~13, 2022, 241,084,780 shares of the Registrant’s Common Stock were outstanding.

Anthem, Inc.

Quarterly Report on Form 10-Q

For the Period Ended March 31, ~~2021~~2022

Table of Contents


		Page
PART I. FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS

	Consolidated Balance Sheets as ofMarch 31,~~, 202~~1 2022 ~~(Unaudited)~~(Unaudited) and December 31, 2~~020~~2021	2
	Consolidated Statements of Income (Unaudited) for the Three Months Ended March 3 1 ~~, 202~~1 31, 2022 and 20 202021	3
	Consolidated Statements of Comprehensive Income (Unaudited) for the Three Months Ended March 3 1 ~~, 202~~1 31, 2022 and 20 202021	4
	Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 3 1 ~~, 202~~1 31, 2022 and 20 202021	5
	Consolidated Statements of Shareholders’ Equity (Unaudited) for the Three Months Ended March 3 1 ~~, 202~~1 31, 2022 and 20 202021	6
	Notes to Consolidated Financial Statements (Unaudited)	7

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	3837
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	5452
ITEM 4.	CONTROLS AND PROCEDURES	5452
PART II. OTHER INFORMATION
ITEM 1.	LEGAL PROCEEDINGS	5452
ITEM 1A.	RISK FACTORS	5452
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	5553
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	5553
ITEM 4.	MINE SAFETY DISCLOSURES	5553
ITEM 5.	OTHER INFORMATION	5553
ITEM 6.	EXHIBITS	5654
SIGNATURES		5755

-1-

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Anthem, Inc.

Consolidated Balance Sheets

March 31,
2021 December 31,
2020
(In millions, except share data) (Unaudited)
Assets
Current assets:
Cash and cash equivalents $ 9,326 $ 5,741
Fixed maturity securities (amortized cost of $23,808 and $22,222; allowance for credit losses of $8 and $7) 24,555 23,433
Equity securities 3,630 1,559
Premium receivables 6,111 5,279
Self-funded receivables 3,109 2,849
Other receivables 3,071 2,830
Other current assets 4,693 4,060
Total current assets 54,495 45,751
Long-term investments:
Fixed maturity securities (amortized cost of $537 and $532; allowance for credit losses of $0 and $0) 558 562
Other invested assets 4,474 4,285
Property and equipment, net 3,533 3,483
Goodwill 21,708 21,691
Other intangible assets 9,352 9,405
Other noncurrent assets 1,563 1,438
Total assets $ 95,683 $ 86,615
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable $ 12,347 $ 11,359
Other policyholder liabilities 5,075 4,590
Unearned income 1,139 1,259
Accounts payable and accrued expenses 5,329 5,493
Current portion of long-term debt 700 700
Other current liabilities 10,159 6,052
Total current liabilities 34,749 29,453
Long-term debt, less current portion 22,534 19,335
Reserves for future policy benefits 776 794
Deferred tax liabilities, net 1,961 2,019
Other noncurrent liabilities 1,745 1,815
Total liabilities 61,765 53,416
Commitments and contingencies – Note 11 0 0
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none 0 0
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
244,938,635 and 245,401,430
2 3
Additional paid-in capital 9,253 9,244
Retained earnings 24,793 23,802
Accumulated other comprehensive (loss) income (195) 150
Total shareholders’ equity 33,853 33,199
Noncontrolling interests 65 0
Total equity 33,918 33,199
Total liabilities and equity $ 95,683 $ 86,615


	March 31, 2022		December 31, 2021
(In millions, except share data)	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	6,161	$	4,880
Fixed maturity securities (amortized cost of $26,971 and $25,641; allowance for credit losses of $13 and $6)	26,219		26,267
Equity securities	1,662		1,881


Premium receivables	7,349		5,681
Self-funded receivables	3,979		4,010
Other receivables	3,334		3,749


Other current assets	5,193		4,654
Total current assets	53,897		51,122
Long-term investments:
Fixed maturity securities (amortized cost of $612 and $616; allowance for credit losses of $0 and $0)	596		632

Other invested assets	5,365		5,225
Property and equipment, net	3,986		3,919
Goodwill	24,251		24,228
Other intangible assets	10,588		10,615
Other noncurrent assets	1,803		1,719
Total assets	$	100,486	$	97,460

Liabilities and equity
Liabilities
Current liabilities:

Medical claims payable	$	14,713	$	13,518

Other policyholder liabilities	5,396		5,521

Unearned income	1,210		1,153
Accounts payable and accrued expenses	5,493		4,970



Short-term borrowings	275		275
Current portion of long-term debt	3,097		1,599
Other current liabilities	9,549		7,849
Total current liabilities	39,733		34,885
Long-term debt, less current portion	19,883		21,157
Reserves for future policy benefits	811		802
Deferred tax liabilities, net	2,349		2,805
Other noncurrent liabilities	1,679		1,683
Total liabilities	64,455		61,332

Commitments and contingencies – Note 11	0		0

Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none	—		—
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 241,140,929 and 241,770,746	2		2
Additional paid-in capital	9,151		9,148
Retained earnings	28,058		27,088
Accumulated other comprehensive loss	(1,236)		(178)
Total shareholders’ equity	35,975		36,060
Noncontrolling interests	56		68
Total equity	36,031		36,128
Total liabilities and equity	$	100,486	$	97,460

See accompanying notes.

-2-

Anthem, Inc.

Consolidated Statements of Income

(Unaudited)


		Three Months Ended March 31				Three Months Ended March 31
(In millions, except per share data)	(In millions, except per share data)	2021		2020			(In millions, except per share data)	2022		2021
Revenues	Revenues						Revenues
Premiums	Premiums	$	27,676	$	25,517		Premiums	$	32,785	$	27,676
Product revenue	Product revenue	2,737		2,344			Product revenue	3,301		2,737
Administrative fees and other revenue	Administrative fees and other revenue	1,685		1,587			Administrative fees and other revenue	1,800		1,685
Total operating revenue	Total operating revenue	32,098		29,448			Total operating revenue	37,886		32,098
Net investment income	Net investment income	291		254			Net investment income	360		291
Net realized losses on financial instruments		(4)		(81)
Net losses on financial instruments							Net losses on financial instruments	(151)		(4)
Total revenues	Total revenues	32,385		29,621			Total revenues	38,095		32,385
Expenses	Expenses						Expenses
Benefit expense	Benefit expense	23,699		21,489			Benefit expense	28,215		23,699
Cost of products sold	Cost of products sold	2,313		1,984			Cost of products sold	2,883		2,313
Selling, general and administrative expense	Selling, general and administrative expense	3,925		3,781			Selling, general and administrative expense	4,341		3,925
Interest expense	Interest expense	192		194			Interest expense	201		192
Amortization of other intangible assets	Amortization of other intangible assets	80		83			Amortization of other intangible assets	129		80
Loss on extinguishment of debt		0		1

Total expenses	Total expenses	30,209		27,532			Total expenses	35,769		30,209
Income before income tax expense	Income before income tax expense	2,176		2,089			Income before income tax expense	2,326		2,176
Income tax expense	Income tax expense	509		566			Income tax expense	531		509

Net income	Net income	1,667		1,523			Net income	1,795		1,667
Net income attributable to noncontrolling interests		(2)		0
Net loss (income) attributable to noncontrolling interests							Net loss (income) attributable to noncontrolling interests	10		(2)
Shareholders’ net income	Shareholders’ net income	$	1,665	$	1,523		Shareholders’ net income	$	1,805	$	1,665
Shareholders’ net income per share	Shareholders’ net income per share						Shareholders’ net income per share

Basic	Basic	$	6.80	$	6.03		Basic	$	7.48	$	6.80

Diluted	Diluted	$	6.71	$	5.94		Diluted	$	7.39	$	6.71
Dividends per share	Dividends per share	$	1.13	$	0.95		Dividends per share	$	1.28	$	1.13

See accompanying notes.

-3-

Anthem, Inc.

Consolidated Statements of Comprehensive Income

(Unaudited)


		Three Months Ended March 31					Three Months Ended March 31
(In millions)	(In millions)	2021		2020		(In millions)		2022		2021
Net income	Net income	$	1,667	$	1,523	Net income		$	1,795	$	1,667
Other comprehensive loss, net of tax:
Other comprehensive (loss) income, net of tax:						Other comprehensive (loss) income, net of tax:
Change in net unrealized losses/gains on investments	Change in net unrealized losses/gains on investments	(362)		(689)		Change in net unrealized losses/gains on investments		(1,069)		(362)
Change in non-credit component of impairment losses on investments	Change in non-credit component of impairment losses on investments	1		(32)		Change in non-credit component of impairment losses on investments		(1)		1
Change in net unrealized gains/losses on cash flow hedges	Change in net unrealized gains/losses on cash flow hedges	4		3		Change in net unrealized gains/losses on cash flow hedges		3		4
Change in net periodic pension and postretirement costs	Change in net periodic pension and postretirement costs	10		7		Change in net periodic pension and postretirement costs		7		10
Foreign currency translation adjustments	Foreign currency translation adjustments	0		(1)		Foreign currency translation adjustments		(3)		—
Other comprehensive loss	Other comprehensive loss	(347)		(712)		Other comprehensive loss		(1,063)		(347)
Net income attributable to noncontrolling interests		(2)		0
Net loss (income) attributable to noncontrolling interests						Net loss (income) attributable to noncontrolling interests		10		(2)
Other comprehensive loss attributable to noncontrolling interests	Other comprehensive loss attributable to noncontrolling interests	2		0		Other comprehensive loss attributable to noncontrolling interests		5		2
Total shareholders’ comprehensive income	Total shareholders’ comprehensive income	$	1,320	$	811	Total shareholders’ comprehensive income		$	747	$	1,320

See accompanying notes.

-4-

Anthem, Inc.

Consolidated Statements of Cash Flows

(Unaudited)


		Three Months Ended March 31					Three Months Ended March 31
(In millions)	(In millions)	2021		2020		(In millions)	2022		2021
Operating activities	Operating activities					Operating activities
Net income	Net income	$	1,667	$	1,523	Net income	$	1,795	$	1,667
Adjustments to reconcile net income to net cash provided by operating activities:	Adjustments to reconcile net income to net cash provided by operating activities:					Adjustments to reconcile net income to net cash provided by operating activities:
Net realized losses on financial instruments		4		81
Net losses on financial instruments						Net losses on financial instruments	151		4
Equity in net earnings of other invested assets						Equity in net earnings of other invested assets	(153)		(108)
Depreciation and amortization	Depreciation and amortization	282		270		Depreciation and amortization	358		282

Deferred income taxes	Deferred income taxes	31		57		Deferred income taxes	(92)		31

Share-based compensation	Share-based compensation	64		67		Share-based compensation	50		64

Changes in operating assets and liabilities:	Changes in operating assets and liabilities:					Changes in operating assets and liabilities:
Receivables, net	Receivables, net	(1,258)		(639)		Receivables, net	(1,348)		(1,258)
Other invested assets	Other invested assets	(20)		63		Other invested assets	7		(20)
Other assets	Other assets	(288)		(525)		Other assets	(353)		(288)
Policy liabilities	Policy liabilities	1,455		692		Policy liabilities	1,075		1,455
Unearned income	Unearned income	(119)		(109)		Unearned income	57		(119)
Accounts payable and other liabilities	Accounts payable and other liabilities	358		588		Accounts payable and other liabilities	428		358

Income taxes	Income taxes	438		491		Income taxes	568		438
Other, net	Other, net	(109)		(44)		Other, net	(2)		(1)
Net cash provided by operating activities	Net cash provided by operating activities	2,505		2,515		Net cash provided by operating activities	2,541		2,505
Investing activities	Investing activities					Investing activities

Purchases of investments	Purchases of investments	(6,978)		(3,896)		Purchases of investments	(5,050)		(6,978)
Proceeds from sale of investments	Proceeds from sale of investments	4,650		2,728		Proceeds from sale of investments	3,047		4,650
Maturities, calls and redemptions from investments	Maturities, calls and redemptions from investments	998		597		Maturities, calls and redemptions from investments	1,209		998

Changes in securities lending collateral	Changes in securities lending collateral	(731)		(77)		Changes in securities lending collateral	(441)		(731)
Purchases of subsidiaries, net of cash acquired	Purchases of subsidiaries, net of cash acquired	(27)		(1,908)		Purchases of subsidiaries, net of cash acquired	(61)		(27)

Purchases of property and equipment	Purchases of property and equipment	(204)		(204)		Purchases of property and equipment	(254)		(204)

Other, net	Other, net	(15)		(24)		Other, net	(28)		(15)
Net cash used in investing activities	Net cash used in investing activities	(2,307)		(2,784)		Net cash used in investing activities	(1,578)		(2,307)
Financing activities	Financing activities					Financing activities
Net (repayments of) proceeds from commercial paper borrowings		(250)		905
Net proceeds from (repayments of) commercial paper borrowings						Net proceeds from (repayments of) commercial paper borrowings	225		(250)
Proceeds from long-term borrowings	Proceeds from long-term borrowings	3,462		300		Proceeds from long-term borrowings	—		3,462
Repayments of long-term borrowings	Repayments of long-term borrowings	0		(52)		Repayments of long-term borrowings	(14)		—
Proceeds from short-term borrowings		0		1,075
Repayments of short-term borrowings		0		(700)

Changes in securities lending payable	Changes in securities lending payable	731		77		Changes in securities lending payable	441		731

Repurchase and retirement of common stock	Repurchase and retirement of common stock	(447)		(529)		Repurchase and retirement of common stock	(545)		(447)

Cash dividends	Cash dividends	(277)		(240)		Cash dividends	(309)		(277)
Proceeds from issuance of common stock under employee stock plans	Proceeds from issuance of common stock under employee stock plans	89		44		Proceeds from issuance of common stock under employee stock plans	76		89
Taxes paid through withholding of common stock under employee stock plans	Taxes paid through withholding of common stock under employee stock plans	(91)		(107)		Taxes paid through withholding of common stock under employee stock plans	(86)		(91)

Other, net	Other, net	171		(94)		Other, net	534		171
Net cash provided by financing activities	Net cash provided by financing activities	3,388		679		Net cash provided by financing activities	322		3,388
Effect of foreign exchange rates on cash and cash equivalents	Effect of foreign exchange rates on cash and cash equivalents	(1)		(2)		Effect of foreign exchange rates on cash and cash equivalents	(4)		(1)
Change in cash and cash equivalents	Change in cash and cash equivalents	3,585		408		Change in cash and cash equivalents	1,281		3,585
Cash and cash equivalents at beginning of period	Cash and cash equivalents at beginning of period	5,741		4,937		Cash and cash equivalents at beginning of period	4,880		5,741
Cash and cash equivalents at end of period	Cash and cash equivalents at end of period	$	9,326	$	5,345	Cash and cash equivalents at end of period	$	6,161	$	9,326

See accompanying notes.

-5-

Anthem, Inc.

Consolidated Statements of Shareholders’ Equity

(Unaudited)

Common Stock Additional
Paid-in
Capital Retained
Earnings Accumulated
Other
Comprehensive
Income (Loss) Noncontrolling Interests Total
Equity
(In millions) Number of
Shares Par
Value
January 1, 2021 245.4 $ 3 $ 9,244 $ 23,802 $ 150 $ 0 $ 33,199
Net income — — — 1,665 — 2 1,667
Other comprehensive loss — — — — (345) (2) (347)
Noncontrolling interests adjustment — — — — — 65 65
Repurchase and retirement of common stock (1.4) (1) (53) (393) — — (447)
Dividends and dividend equivalents — — — (281) — — (281)
Issuance of common stock under employee stock plans, net of related tax benefits 0.9 — 62 — — — 62
March 31, 2021 244.9 $ 2 $ 9,253 $ 24,793 $ (195) $ 65 $ 33,918
December 31, 2019 (audited) 252.9 $ 3 $ 9,448 $ 22,573 $ (296) $ — $ 31,728
Adoption of Accounting Standards Update No. 2016-13 — — — (35) — — (35)
January 1, 2020 252.9 3 9,448 22,538 (296) — 31,693
Net income — — — 1,523 — — 1,523
Other comprehensive loss — — — — (712) — (712)
Repurchase and retirement of common stock (1.9) — (71) (458) — — (529)
Dividends and dividend equivalents — — — (243) — — (243)
Issuance of common stock under employee stock plans, net of related tax benefits 1.0 — 3 — — — 3
Convertible debenture repurchases and conversions — — (42) — — — (42)
March 31, 2020 252.0 $ 3 $ 9,338 $ 23,360 $ (1,008) $ — $ 31,693



	Common Stock			Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive (Loss) Income		Noncontrolling Interests		Total Equity
(In millions)	Number of Shares	Par Value


December 31, 2021 (audited)	241.8	$	2	$	9,148	$	27,088	$	(178)	$	68	$	36,128
Adoption of Accounting Standards Update 2020-06 (Note 2)	—	—		—		(23)		—		—		(23)
January 1, 2022	241.8	2		9,148		27,065		(178)		68		36,105
Net income	—	—		—		1,805		—		(10)		1,795
Other comprehensive loss	—	—		—		—		(1,058)		(5)		(1,063)


Noncontrolling interests adjustment	—	—		—		—		—		3		3
Repurchase and retirement of common stock	(1.2)	—		(45)		(500)		—		—		(545)
Dividends and dividend equivalents	—	—		—		(312)		—		—		(312)
Issuance of common stock under employee stock plans, net of related tax benefits	0.5	—		39		—		—		—		39
Convertible debenture repurchases, conversions and tax adjustments	—	—		9		—		—		—		9
March 31, 2022	241.1	$	2	$	9,151	$	28,058	$	(1,236)	$	56	$	36,031























January 1, 2021	245.4	$	3	$	9,244	$	23,802	$	150	$	—	$	33,199
Net income	—	—		—		1,665		—		2		1,667
Other comprehensive loss	—	—		—		—		(345)		(2)		(347)
Accumulated noncontrolling interest	—	—		—		—		—		65		65
Repurchase and retirement of common stock	(1.4)	(1)		(53)		(393)		—		—		(447)
Dividends and dividend equivalents	—	—		—		(281)		—		—		(281)
Issuance of common stock under employee stock plans, net of related tax benefits	0.9	—		62		—		—		��		62

March 31, 2021	244.9	$	2	$	9,253	$	24,793	$	(195)	$	65	$	33,918

See accompanying notes.

-6-

Anthem, Inc.

Notes to Consolidated Financial Statements

(Unaudited)

March 31, ~~2021~~2022

(In Millions, Except Per Share Data or As Otherwise Stated Herein)

1. Organization

References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires. On March 10, 2022, we announced our intent to change our name to better reflect our business and our journey from a traditional health benefits organization to a lifetime, trusted health partner. At our annual meeting of shareholders on May 18, 2022, our shareholders will vote on a proposed amendment to our amended and restated articles of incorporation to change our name to Elevance Health, Inc. Shareholders of record on March 17, 2022 are entitled to vote. If approved by our shareholders, we expect the name change to occur in the second quarter of 2022.

We are one of the largest health benefits companies in the United States in terms of medical membership, serving nearly 4447 million medical members through our affiliated health plans as of March 31, ~~2021.~~2022. We offer a broad spectrum of network-based managed care risk-based plans to Individual, Group, Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations (“PPOs”); Health Maintenance Organizations (“HMOs”); Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit products. In addition, we provide a broad array of managed care services to fee-based customers, including claims processing, stop loss insurance, ~~actuarial services,~~ provider network access, medical ~~cost~~ management, ~~disease~~care management and wellness programs, actuarial services and other administrative services. We provide an array of specialty and other insurance products and services such as pharmacy benefits management (“PBM”), dental, vision, life and disability insurance benefits, radiology benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products & Services business, which administers the Federal Employees Health Benefits (“FEHB”) Program. We provide an array of specialty services both to our subsidiary health plans and also unaffiliated health plans, including pharmacy benefits management (“PBM”) services and dental, vision, life, disability and supplemental health insurance benefits, as well as integrated health services.

We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. ~~We also~~In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states ~~across the country~~ as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. ~~Also, we provide~~We offer PBM services through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, ~~and~~ the District of Columbia and Puerto Rico through our subsidiaries.

2. Basis of Presentation and Significant Accounting Policies

Basis of Presentation: The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our ~~2020~~2021 Annual Report on Form 10-K, unless the information contained in those disclosures materially changed or is required by GAAP. ~~Certain prior year amounts have been reclassified to conform to the current year presentation.~~ In the opinion of management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 have been recorded. The results of operations for the three months ended March 31, ~~2021~~2022 are not necessarily indicative of the results that may be expected for the full year ending December 31, ~~2021,~~2022, or any other period. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements as of and for the year ended December 31, ~~2020~~2021 included in our ~~2020~~2021 Annual Report on Form 10-K.

Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar (“USD”). We translate the assets and liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the

-7-

period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during

~~-7-~~

the period. The net effect of these translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.

Cash and Cash Equivalents: We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled ~~$205~~$162 and ~~$170~~$173 at March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.

Investments: We classify fixed maturity securities in our investment portfolio as “available-for-sale” and report those securities at fair value. Certain fixed maturity securities are available to support current operations and, accordingly, we classify such investments as current assets without regard to their contractual maturity. Investments used to satisfy contractual, regulatory or other requirements are classified as long-term, without regard to contractual maturity.

If a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in accumulated other comprehensive ~~(loss) income.~~loss.

The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and estimates regarding timing and amount of recoveries associated with a default.

For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since the purchase date of the securities. Such adjustments are reported within net investment income.

The changes in fair value of our marketable equity securities are recognized in our results of operations within net ~~realized~~ gains and losses on financial instruments. Certain marketable equity securities are held to satisfy contractual obligations, and are reported under the caption “Other invested assets” in our consolidated balance sheets.

We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.

We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.

Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.

-8-

We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. We recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on securities lending collateral are included in accumulated other comprehensive ~~(loss) income~~loss as a separate component of shareholders’ equity. The market value of loaned securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 102% of the value of the loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting the investments to higher quality and shorter duration instruments.

Receivables: Receivables are reported net of amounts for expected credit losses. The allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.

Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are reported net of an allowance for doubtful accounts of ~~$146~~$140 and $142 at ~~each of~~ March 31, ~~2021~~2022 and December 31, ~~2020.~~2021, respectively.

Self-funded receivables include administrative fees, claims and other amounts due from self-funded customers. Self-funded receivables are reported net of an allowance for doubtful accounts of ~~$51~~$53 and ~~$54~~$50 at March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively.

Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades, accrued investment income, and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of ~~$406~~$698 and ~~$374~~$648 at March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively.

Revenue Recognition: For our ~~fee-based~~non-risk-based contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our consolidated balance sheet at March 31, ~~2021.~~2022. For the three months ended March 31, 2022 and 2021, revenue recognized from performance obligations related to prior periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to undelivered performance obligations is not material.

Recently Adopted Accounting Guidance: In January 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2021-01, Reference Rate Reform (Topic 848) (“ASU 2021-01”). The amendments in ASU 2021-01 provide optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. We adopted ASU 2021-01 on January 7, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.

In October 2020, the FASB issued Accounting Standards Update No. 2020-08, Codification Improvements to Subtopic 310-20, Receivables—Nonrefundable Fees and Other Costs (“ASU 2020-08”). The amendments in ASU 2020-08 clarify when an entity should assess whether a callable debt security is within the scope of accounting guidance, which impacts the amortization period for nonrefundable fees and other costs. ASU 2020-08 became effective for interim and annual reporting periods beginning after December 15, 2020. The amendments ~~are~~were to be applied on a prospective basis as of the beginning of the period of adoption for existing or newly purchased callable debt securities. We adopted ASU 2020-08 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.

In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting

-9-

for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”). The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments became effective for our annual and interim reporting periods beginning after December 15, 2021. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease to our deferred tax liabilities of $8, and a corresponding cumulative-effect reduction to our opening retained earnings of $23; the amounts are not material to our overall consolidated financial position. The adoption of ASU 2020-06 did not have an impact on our results of operations or our consolidated cash flows. Use of the if-converted method did not have an impact on our overall earnings per share calculation.

In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). The amendments in ASU 2019-12 remove certain exceptions to the

~~-9-~~

general principles in Accounting Standards Codification Topic 740. The amendments also clarify and amend existing guidance to improve consistent application. The amendments became effective for our annual reporting periods beginning after December 15, 2020. The transition method (retrospective, modified retrospective, or prospective basis) related to the amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis. We adopted ASU 2019-12 on January 1, 2021, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.

Recent Accounting Guidance Not Yet Adopted: In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application (“ASU 2020-11”). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services—Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (“ASU 2018-12”), which was issued in November 2018. The amendments in ASU 2020-11 have extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to measure their liabilities and how they may affect future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2020-11 and ASU 2018-12 will have on our consolidated financial position, results of operations, cash flows, and related disclosures.

~~In August 2020, the FASB issued Accounting Standards Update No. 2020-06,~~ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity ~~(“ASU 2020-06”)~~. The amendments eliminate two of the three accounting models that require separate accounting for convertible features of debt securities, simplify the contract settlement assessment for equity classification, require the use of the if-converted method for all convertible instruments in the diluted earnings per share calculation and expand disclosure requirements. The amendments are effective for our annual and interim reporting periods beginning after December 15, 2021, with early adoption permitted for reporting periods beginning after December 15, 2020. The guidance can be applied on a full retrospective basis to all periods presented or a modified retrospective basis with a cumulative effect adjustment to the opening balance of retained earnings during the period of adoption. We are currently evaluating the effects the adoption of ASU 2020-06 will have on our consolidated financial statements and disclosures.

There were no other new accounting pronouncements that were issued or became effective since the issuance of our ~~2020~~2021 Annual Report on Form 10-K that had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.

3. Business Acquisitions

Pending Acquisition ~~of myNEXUS, Inc.~~

On ~~March 24,~~November 10, 2021, we announced our entrance into an agreement with ~~WindRose Health Investors~~Personal Touch Holding Corporation to acquire ~~myNEXUS, Inc.~~Integra Managed Care (“~~myNEXUS”~~Integra”). ~~myNEXUS~~Integra is a ~~comprehensive home-based nursing management company for payors~~managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and ~~delivers integrated clinical support services for Medicare Advantage members across twenty states. This acquisition aligns with our strategy~~disabilities to ~~manage integrated, whole person multi-site care~~live safely and ~~support, by providing national, large-scale expertise to manage nursing services~~independently in ~~the home and facilitate transitions of care.~~their own home. The acquisition is expected to close by the end of the second quarter of ~~2021~~2022 and is subject to standard closing conditions and customary approvals.

-10-

~~Pending Acquisition~~Completed Acquisitions

Acquisitions completed during the year ended December 31, 2021, for which the initial accounting was not finalized as of ~~MMM Holdings LLC~~March 31, 2022, included myNEXUS, Inc. (“myNEXUS”), a comprehensive home-based nursing management company for payors, and ~~Affiliates~~

~~On February 2, 2021, we announced our entrance into an agreement with InnovaCare Health, L.P. to acquire its Puerto Rico-based subsidiaries, including~~ MMM Holdings, LLC (“MMM”), including its Medicare Advantage plan, Medicaid plan and other affiliated companies. ~~MMM is an integrated healthcare organization and seeks to provide its Medicare Advantage and Medicaid members with a whole health experience through its network~~As of specialized clinics and wholly owned independent physician associations. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improveMarch 31, 2022, the ~~lives~~purchase price of ~~the people we serve. The acquisition is expected to close by the end of the second quarter of 2021 and is subject to standard closing conditions and customary approvals.~~

~~Beacon Health Options, Inc.~~

On February 28, 2020, we completed our acquisition of Beacon Health Options, Inc. (“Beacon”) which was the largest independently held behavioral health organization in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligned with our strategy to diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions.

~~In accordance with FASB accounting guidance for business combinations, the consideration transferred~~each transaction was allocated to the ~~fair value of Beacon’s assets acquired~~tangible and ~~liabilities assumed, including identifiable~~ intangible ~~assets. The excess of the consideration transferred over the fair value of~~ net assets acquired ~~resulted in preliminary goodwill~~based on management’s final estimates of ~~$1,072 at December 31, 2020, all~~their fair values, of which ~~was~~$1,577 has been allocated to ~~our Other segment. Preliminary~~finite-lived intangible assets, $20 to indefinite-lived intangible assets, and $2,525 to goodwill. The majority of goodwill ~~recognized~~is not deductible for income tax purposes. Adjustments to goodwill arising from ~~the acquisition of Beacon primarily relates~~contractual purchase price adjustments and subsequent adjustments made to ~~the future economic benefits arising from~~ the assets acquired ~~and is consistent with our stated intentions and strategy. Goodwill was adjusted by $9 through~~or liabilities assumed during the ~~end of the measurement period in February 2021 related to finalization of income tax considerations, resulting in final goodwill of $1,081 as of~~quarter ended March 31, ~~2021.~~

The fair value of the net assets acquired from Beacon includes $752 of other intangible assets at March 31, 2021, which primarily consist of finite-lived customer relationships with amortization periods ranging from 8 to 25 years. The results of operations of Beacon are included in our consolidated financial statements within our Other segment for the period following February 28, 2020. The pro forma effects of this acquisition for prior periods2022 were ~~not material to our consolidated results of operations.~~$4.

4. Business Optimization Initiatives

~~During 2020, management introduced enterprise-wide initiatives to optimize our business, including process automation and~~Provided below is a reduction in our office space footprint and, as a result, we recognized a liability in 2020 for future payments for employee termination costs in connection with the repositioning and reskilling of our workforce. We believe these initiatives largely represent the next step forward in our progression towards becoming a more agile organization.

A summary of the activity, by reportable segment, related to the liability for ~~the~~ employee termination costs ~~during the three months ended March 31, 2021, by reportable segment, is as follows:~~previously incurred in connection with our enterprise-wide business optimization initiatives introduced in 2020.


		Commercial & Specialty Business		Government Business		IngenioRx		Other		Total			Commercial & Specialty Business		Government Business		IngenioRx		Other		Total
2020 Business Optimization Initiatives	2020 Business Optimization Initiatives											2020 Business Optimization Initiatives
Employee termination costs:	Employee termination costs:											Employee termination costs:
Liability for employee termination costs at January 1, 2021		$	92	$	88	$	1	$	6	$	187
Liability for employee termination costs at January 1, 2022												Liability for employee termination costs at January 1, 2022	$	61	$	57	$	1	$	3	$	122

Payments	Payments	(5)		(5)		0		(1)		(11)		Payments	(5)		(5)		—		—		(10)
Liability for employee termination costs at March 31, 2021		$	87	$	83	$	1	$	5	$	176
Liability for employee termination costs at March 31, 2022												Liability for employee termination costs at March 31, 2022	$	56	$	52	$	1	$	3	$	112

~~-11-~~

5. Investments

Fixed Maturity Securities

We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. We have established an allowance for credit loss and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value may occur and additional material impairment losses on investments may be recorded in future periods.

Although not material to our consolidated results of operations, during the three months ended March 31, 2022, we recorded a combination of credit losses, losses on sale of fixed maturity securities and impairments related to our exposure resulting from investments in Russia and Ukraine. These items are reflected in the tables presented below. At March 31, 2022, our remaining holdings of Russia and Ukraine fixed maturity securities were not material.

-11-

A summary of current and long-term fixed maturity securities, available-for-sale, at March 31, ~~2021~~2022 and December 31, ~~2020~~2021 is as follows:


		Cost or Amortized Cost																Non-Credit Component of Impairment Recognized in Accumulated Other Comprehensive Loss				Cost or Amortized Cost				Gross Unrealized Gains				Gross Unrealized Losses				Allowance For Credit Losses				Estimated Fair Value
				Gross Unrealized Gains			Gross Unrealized Losses					Allowance For Credit Losses			Estimated Fair Value
								Less than 12 Months		12 Months or Greater
March 31, 2021
March 31, 2022																				March 31, 2022
Fixed maturity securities:	Fixed maturity securities:																			Fixed maturity securities:
United States Government securities	United States Government securities	$	898		$	4		$	(22)	$	0		$	0		$	880			$	0		United States Government securities	$	2,145			$	—			$	(78)			$	—			$	2,067
Government sponsored securities	Government sponsored securities	71			4			0		0			0			75		0		Government sponsored securities		54				2				(2)				—				54
Foreign government securities	Foreign government securities	341			5			(9)		(1)			0			336		0		Foreign government securities		343				2				(25)				(3)				317
States, municipalities and political subdivisions	States, municipalities and political subdivisions	5,253			327			(13)		(1)			0			5,566		0		States, municipalities and political subdivisions		5,369				84				(126)				—				5,327
Corporate securities	Corporate securities	11,228			466			(76)		(13)			(6)			11,599		(1)		Corporate securities		12,361				104				(491)				(8)				11,966

Residential mortgage-backed securities	Residential mortgage-backed securities	4,258			117			(25)		(9)			(2)			4,339		0		Residential mortgage-backed securities		4,262				18				(174)				(2)				4,104
Commercial mortgage-backed securities	Commercial mortgage-backed securities	70			3			0		(3)			0			70		0		Commercial mortgage-backed securities		82				1				(4)				—				79
Other securities	Other securities	2,226			30			(2)		(6)			0			2,248		0		Other securities		2,967				13				(79)				—				2,901
Total fixed maturity securities	Total fixed maturity securities	$	24,345		$	956		$	(147)	$	(33)		$	(8)		$	25,113	$	(1)	Total fixed maturity securities		$	27,583			$	224			$	(979)			$	(13)			$	26,815

December 31, 2020
December 31, 2021																				December 31, 2021
Fixed maturity securities:	Fixed maturity securities:																			Fixed maturity securities:
United States Government securities	United States Government securities	$	765		$	11		$	(2)	$	0		$	0		$	774	$	0	United States Government securities		$	1,443			$	7			$	(18)			$	—			$	1,432
Government sponsored securities	Government sponsored securities	63			6			0		0			0			69		0		Government sponsored securities		65				4				(1)				—				68
Foreign government securities	Foreign government securities	290			17			(2)		0			0			305		0		Foreign government securities		353				7				(13)				—				347
States, municipalities and political subdivisions	States, municipalities and political subdivisions	5,185			395			(1)		0			0			5,579		0		States, municipalities and political subdivisions		5,321				310				(10)				—				5,621
Corporate securities	Corporate securities	10,233			697			(20)		(11)			(7)			10,892		(1)		Corporate securities		12,044				401				(78)				(4)				12,363

Residential mortgage-backed securities	Residential mortgage-backed securities	4,208			154			(8)		(9)			0			4,345		(2)		Residential mortgage-backed securities		4,059				75				(35)				(2)				4,097
Commercial mortgage-backed securities	Commercial mortgage-backed securities	73			3			(1)		(3)			0			72		0		Commercial mortgage-backed securities		65				2				(3)				—				64
Other securities	Other securities	1,937			33			(5)		(6)			0			1,959		0		Other securities		2,907				24				(24)				—				2,907
Total fixed maturity securities	Total fixed maturity securities	$	22,754		$	1,316		$	(39)	$	(29)		$	(7)		$	23,995	$	(3)	Total fixed maturity securities		$	26,257			$	830			$	(182)			$	(6)			$	26,899

-12-

For fixed maturity securities in an unrealized loss position at March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, the following table summarizes the aggregate fair values and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:


		Less than 12 Months					12 Months or Greater						Less than 12 Months					12 Months or Greater
(Securities are whole amounts)	(Securities are whole amounts)	Number of Securities	Estimated Fair Value		Gross Unrealized Loss		Number of Securities	Estimated Fair Value		Gross Unrealized Loss		(Securities are whole amounts)	Number of Securities	Estimated Fair Value		Gross Unrealized Loss		Number of Securities	Estimated Fair Value		Gross Unrealized Loss
March 31, 2021
March 31, 2022												March 31, 2022
Fixed maturity securities:	Fixed maturity securities:											Fixed maturity securities:
United States Government securities	United States Government securities	51	$	654	$	(22)	0	$	0	$	0	United States Government securities	86	$	1,801	$	(66)	20	$	149	$	(12)
Government sponsored securities	Government sponsored securities	2	2		0		0	0		0		Government sponsored securities	25	21		(1)		1	1		(1)
Foreign government securities	Foreign government securities	202	177		(9)		26	17		(1)		Foreign government securities	233	205		(15)		95	54		(10)
States, municipalities and political subdivisions	States, municipalities and political subdivisions	242	495		(13)		7	13		(1)		States, municipalities and political subdivisions	1,140	2,088		(123)		23	25		(3)
Corporate securities	Corporate securities	1,735	2,707		(76)		241	291		(13)		Corporate securities	3,616	7,520		(423)		532	620		(68)
Residential mortgage-backed securities	Residential mortgage-backed securities	363	1,489		(25)		125	156		(9)		Residential mortgage-backed securities	1,547	3,142		(137)		184	419		(37)
Commercial mortgage-backed securities	Commercial mortgage-backed securities	1	2		0		6	13		(3)		Commercial mortgage-backed securities	21	51		(1)		5	9		(3)
Other securities	Other securities	160	456		(2)		70	149		(6)		Other securities	746	2,240		(70)		84	183		(9)
Total fixed maturity securities	Total fixed maturity securities	2,756	$	5,982	$	(147)	475	$	639	$	(33)	Total fixed maturity securities	7,414	$	17,068	$	(836)	944	$	1,460	$	(143)

December 31, 2020
December 31, 2021												December 31, 2021
Fixed maturity securities:	Fixed maturity securities:											Fixed maturity securities:
United States Government securities	United States Government securities	27	$	301	$	(2)	0	$	0	$	0	United States Government securities	51	$	990	$	(11)	27	$	176	$	(7)
Government sponsored securities	Government sponsored securities	0	0		0		1	0		0		Government sponsored securities	—	—		—		1	1		(1)
Foreign government securities	Foreign government securities	55	35		(2)		9	4		0		Foreign government securities	188	143		(8)		68	41		(5)
States, municipalities and political subdivisions	States, municipalities and political subdivisions	36	57		(1)		1	3		0		States, municipalities and political subdivisions	281	634		(9)		8	16		(1)
Corporate securities	Corporate securities	646	765		(20)		150	169		(11)		Corporate securities	1,846	3,310		(57)		403	485		(21)
Residential mortgage-backed securities	Residential mortgage-backed securities	224	442		(8)		90	110		(9)		Residential mortgage-backed securities	692	1,967		(26)		125	173		(9)
Commercial mortgage-backed securities	Commercial mortgage-backed securities	6	16		(1)		3	4		(3)		Commercial mortgage-backed securities	2	4		(1)		4	8		(2)
Other securities	Other securities	207	509		(5)		79	179		(6)		Other securities	511	1,707		(19)		50	85		(5)
Total fixed maturity securities	Total fixed maturity securities	1,201	$	2,125	$	(39)	333	$	469	$	(29)	Total fixed maturity securities	3,571	$	8,755	$	(131)	686	$	985	$	(51)

Below are discussions by security type for unrealized losses and credit losses as of March 31, ~~2021:~~2022:

Foreign government securities: An allowance for credit loss was established on certain foreign government securities related to Russia and the Ukraine. The ongoing Russian/Ukrainian conflict and the uncertainties around future ability to collect payment, as well as a significant decline in fair value, were factors indicating a credit loss. No other foreign government securities had material unrealized losses or qualitative factors to indicate a credit loss.

Corporate securities: An allowance for credit losses on ~~certain retail, travel~~consumer-driven and ~~entertainment and energy~~financial sector fixed maturity corporate securities has been determined based on qualitative and quantitative factors including credit rating, decline in fair value and industry condition along with other available market data. With multiple risk factors present, these securities were reviewed for expected future cash flow to determine the portion of unrealized losses that were credit related and to record an allowance for credit losses. Unrealized losses on our other corporate securities were largely due to market conditions relating to the COVID-19 ~~pandemic;~~pandemic and increasing interest rates; however, qualitative factors did not indicate a credit loss as of March 31, ~~2021.~~2022. We do not intend to sell these investments and it is likely we will not have to sell these investments prior to maturity or recovery of amortized cost.

-13-

Residential mortgage-backed securities: An allowance for credit loss was established on certain residential mortgage-backed securities. Notification of maturity and coupon default, as well as a significant and sustained decline in fair value, were factors to indicate a credit loss. NoUnrealized losses on our other ~~mortgage~~residential mortgage-backed securities ~~had material unrealized losses or~~were largely due to market conditions and rising interest rates; however, qualitative factors todid not indicate a credit loss. We do not intend to sell these investments and it is likely we will not be required to sell these investments prior to maturity or recovery of amortized cost.

~~-13-~~

As for the remaining securities shown in the table above, unrealized losses on these securities have not been recognized into income because we do not intend to sell these investments and it is likely that we will not be required to sell these investments prior to their anticipated recovery. The decline in fair value is largely due to changes in interest rates and other market conditions. We have evaluated these securities for any change in credit rating and have determined that no allowance is necessary. The fair value is expected to recover as the securities approach maturity.

The table below presents a roll-forward by major security type of the allowance for credit losses on fixed maturity securities available-for-sale held at period end for the three months ~~ended~~ March 31, ~~2021~~2022 and ~~2020:~~2021:


							Three Months Ended March 31, 2022
							Foreign government securities				Corporate securities		Residential mortgage-backed securities		Total
Three Months Ended March 31, 2021:			Corporate Securities		Residential mortgage-backed securities			Total
Allowance for credit losses:	Allowance for credit losses:									Allowance for credit losses:
		Beginning balance	$	7	$	0		$	7
		Additions for securities for which no previous expected credit losses were recognized	1		0			1
Beginning balance										Beginning balance	$	—	$	4	$	2	$	6
Additions for securities for which no previous expected credit losses were recognized										Additions for securities for which no previous expected credit losses were recognized	3		4		—		7

		(Decreases) increases to the allowance for credit losses on securities	(2)		2			0
Total allowance for credit losses, ending balance	Total allowance for credit losses, ending balance		$	6	$	2		$	8	Total allowance for credit losses, ending balance	$	3	$	8	$	2	$	13


							Three Months Ended March 31, 2021
							Corporate securities				Residential mortgage-backed securities		Total
Three Months Ended March 31, 2020:			Corporate Securities		Residential mortgage-backed securities			Total
Allowance for credit losses:	Allowance for credit losses:									Allowance for credit losses:
Beginning balance										Beginning balance	$	7	$	—	$	7
Additions for securities for which no previous expected credit losses were recognized										Additions for securities for which no previous expected credit losses were recognized	1		—		1
		Beginning balance	$	0	$	0		$	0
		Additions for securities for which no previous expected credit losses were recognized	51		0			51

(Decreases) increases to the allowance for credit losses on securities										(Decreases) increases to the allowance for credit losses on securities	(2)		2		—

Total allowance for credit losses, ending balance	Total allowance for credit losses, ending balance		$	51	$	0		$	51	Total allowance for credit losses, ending balance	$	6	$	2	$	8

The amortized cost and fair value of fixed maturity securities at March 31, ~~2021,~~2022, by contractual maturity, are shown below. Expected maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations.


		Amortized Cost		Estimated Fair Value			Amortized Cost		Estimated Fair Value
Due in one year or less	Due in one year or less	$	617	$	622	Due in one year or less	$	1,257	$	1,254
Due after one year through five years	Due after one year through five years	6,057		6,293		Due after one year through five years	6,686		6,569
Due after five years through ten years	Due after five years through ten years	8,009		8,225		Due after five years through ten years	9,225		8,905
Due after ten years	Due after ten years	5,334		5,564		Due after ten years	6,071		5,904
Mortgage-backed securities	Mortgage-backed securities	4,328		4,409		Mortgage-backed securities	4,344		4,183
Total fixed maturity securities	Total fixed maturity securities	$	24,345	$	25,113	Total fixed maturity securities	$	27,583	$	26,815

-14-

During the three months ended March 31, ~~2021~~2022 and ~~2020~~2021, we received total proceeds from sales, maturities, calls or redemptions of fixed maturity securities of ~~$5,323~~$3,646 and ~~$1,931,~~$5,323, respectively.

In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or (v) changes in expected cash flow.

All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or amortized cost of the specific securities sold.

~~-14-~~

Equity Securities

A summary of marketable equity securities at March 31, ~~2021~~2022 and December 31, ~~2020~~2021 is as follows:


		March 31, 2021		December 31, 2020			March 31, 2022		December 31, 2021
Equity securities:	Equity securities:					Equity securities:
Exchange traded funds	Exchange traded funds	$	3,409	$	1,154	Exchange traded funds	$	1,539	$	1,750
Fixed maturity mutual funds		0		144

Common equity securities	Common equity securities	156		201		Common equity securities	24		42
Private equity securities	Private equity securities	65		60		Private equity securities	99		89
Total	Total	$	3,630	$	1,559	Total	$	1,662	$	1,881

Other Invested Assets

Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, ~~as well as~~mortgage loans and the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments are reported on a one or three month lag due to the timing of when we receive financial information from the companies.

Investment Gains and Losses

Net ~~realized~~ investment ~~losses~~gains (losses) for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 are as follows:

Three Months Ended March 31
2021 2020
Net realized gains (losses):
Fixed maturity securities:
Gross realized gains from sales $ 56 $ 43
Gross realized losses from sales (12) (20)
Impairment losses recognized in income (1) (51)
Net realized gains (losses) from sales of fixed maturity securities 43 (28)
Equity securities:
Gross realized gains 12 23
Gross realized losses (78) (73)
Net realized losses on equity securities (66) (50)
Other invested assets:
Gross realized gains from sales 5 7
Gross realized losses from sales 0 (1)
Impairment losses recognized in income (8) (6)
Net realized losses from sales of other investments (3) 0
Net realized losses on investments $ (26) $ (78)

~~The gains and losses related to equity securities for the three months ended March 31, 2021 and 2020 are as follows:~~

Three Months Ended March 31
2021 2020
Net realized losses recognized on equity securities $ (66) $ (50)
Less: Net realized gains (losses) recognized on equity securities sold during the period 26 (18)
Unrealized losses recognized on equity securities still held at the end of the period $ (40) $ (68)


	Three Months Ended March 31
	2022		2021
Net (losses) gains:
Fixed maturity securities:
Gross realized gains from sales	$	20	$	56
Gross realized losses from sales	(78)		(12)
Impairment losses recognized in income	(20)		(1)
Net realized (losses) gains from sales of fixed maturity securities	(78)		43
Equity securities:
Unrealized losses recognized on equity securities still held at the end of the period	(71)		(40)
Net realized losses recognized on equity securities sold during the period	(14)		(26)
Net losses on equity securities	(85)		(66)
Other investments:
Gross gains	23		5
Gross losses	(30)		—
Impairment losses recognized in income	(4)		(8)
Net losses on other investments	(11)		(3)
Net losses on investments	$	(174)	$	(26)

-15-

Accrued Investment Income

At March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, accrued investment income totaled $185 and ~~$188,~~$205, respectively. We recognize accrued investment income under the caption “Other receivables” on our consolidated balance sheets.

Securities Lending Programs

We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to ~~$1,930~~$2,596 and ~~$1,199~~$2,155 at March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively. The value of the collateral represented 102% of the market value of the securities on loan at each of March 31, ~~2021~~2022 and December 31, ~~2020.~~2021. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are reported in the applicable investment category on our consolidated balance sheets.

~~The~~At March 31, 2022 and December 31, 2021, the remaining contractual maturity of our securities lending agreements ~~at March 31, 2021 is as follows:~~

~~Overnight and Continuous~~

~~Securities lending collateral~~

~~Cash~~

~~1,695~~

~~United States Government securities~~

~~234~~

~~Other securities~~

~~Total~~

~~1,930~~

included overnight and continuous transactions of cash for $2,408 and $1,874, respectively, of United States Government securities for $184 and $281, respectively, and of Other securities for $4 and $0, respectively.

6. Derivative Financial Instruments

We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions, embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.

We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating rates. The floating rates payable on all of our fair value hedges are benchmarked to ~~LIBOR.~~LIBOR or the Secured Overnight Financing Rate (“SOFR”). Any amounts recognized for changes in fair value of these derivatives are included in the captions “Other current assets,” or “Other noncurrent ~~assets”~~assets,” or “Other current liabilities” or “Other noncurrent liabilities” in our consolidated balance sheets.

We have previously entered into a series of forward starting pay fixed interest rate swaps with the objective of reducing the variability of cash flows in the interest payments on future financings that were anticipated at the time of entering into the swaps. All swaps were expired or terminated as of March 31, 2021.

The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other comprehensive loss, net of tax, was ~~$246~~$236 and ~~$250~~$239 at March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively.

~~During the three months ended March 31, 2021, we recognized net realized gains on non-hedging derivatives of $22.~~ During the three months ended March 31, ~~2020~~2022 and 2021, we recognized net ~~realized losses~~gains on non-hedging derivatives of ~~$3.~~$23 and $22, respectively.

For additional information relating to the fair value of our derivative assets and liabilities, see Note 7, “Fair Value,” of this Form 10-Q.

~~-16-~~

7. Fair Value

Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:


Level Input						Input Definition
Level I						Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II						Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III						Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

-16-

The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value in our consolidated balance sheets:

Cash equivalents: Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.

Fixed maturity securities, available-for-sale: Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities, United States ~~Government~~government securities, foreign government securities, and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, which are designated Level III securities. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

Equity securities: Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities, quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital, long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.

Securities lending collateral: Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements and disclosures.

Derivatives: Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions. Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a master netting basis by counterparty.

-17-

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at March 31, ~~2021~~2022 and December 31, ~~2020~~2021 is as follows:


		Level I		Level II		Level III		Total			Level I		Level II		Level III		Total
March 31, 2021
March 31, 2022										March 31, 2022
Assets:	Assets:									Assets:
Cash equivalents	Cash equivalents	$	5,914	$	0	$	0	$	5,914	Cash equivalents	$	2,831	$	—	$	—	$	2,831
Fixed maturity securities, available-for-sale:	Fixed maturity securities, available-for-sale:									Fixed maturity securities, available-for-sale:
United States Government securities	United States Government securities	0		880		0		880		United States Government securities	—		2,067		—		2,067
Government sponsored securities	Government sponsored securities	0		75		0		75		Government sponsored securities	—		54		—		54
Foreign government securities	Foreign government securities	0		336		0		336		Foreign government securities	—		317		—		317
States, municipalities and political subdivisions, tax-exempt	States, municipalities and political subdivisions, tax-exempt	0		5,566		0		5,566		States, municipalities and political subdivisions, tax-exempt	—		5,327		—		5,327
Corporate securities	Corporate securities	0		11,275		324		11,599		Corporate securities	—		11,625		341		11,966
Residential mortgage-backed securities	Residential mortgage-backed securities	0		4,337		2		4,339		Residential mortgage-backed securities	—		4,100		4		4,104
Commercial mortgage-backed securities	Commercial mortgage-backed securities	0		70		0		70		Commercial mortgage-backed securities	—		79		—		79
Other securities	Other securities	0		2,243		5		2,248		Other securities	—		2,864		37		2,901
Total fixed maturity securities, available-for-sale	Total fixed maturity securities, available-for-sale	0		24,782		331		25,113		Total fixed maturity securities, available-for-sale	—		26,433		382		26,815
Equity securities:	Equity securities:									Equity securities:
Exchange traded funds	Exchange traded funds	3,409		0		0		3,409		Exchange traded funds	1,539		—		—		1,539

Common equity securities	Common equity securities	125		31		0		156		Common equity securities	8		16		—		24
Private equity securities	Private equity securities	0		0		65		65		Private equity securities	—		—		99		99
Total equity securities	Total equity securities	3,534		31		65		3,630		Total equity securities	1,547		16		99		1,662
Other invested assets - common equity securities										Other invested assets - common equity securities	126		—		—		126
Securities lending collateral	Securities lending collateral	0		1,930		0		1,930		Securities lending collateral	—		2,596		—		2,596
Derivatives		0		42		0		42
Derivatives - other assets										Derivatives - other assets	—		9		—		9
Total assets	Total assets	$	9,448	$	26,785	$	396	$	36,629	Total assets	$	4,504	$	29,054	$	481	$	34,039
Liabilities:	Liabilities:									Liabilities:
Derivatives		$	0	$	(11)	$	0	$	(11)
Derivatives - other liabilities										Derivatives - other liabilities	$	—	$	(19)	$	—	$	(19)
Total liabilities	Total liabilities	$	0	$	(11)	$	0	$	(11)	Total liabilities	$	—	$	(19)	$	—	$	(19)

December 31, 2020
December 31, 2021										December 31, 2021
Assets:	Assets:									Assets:
Cash equivalents	Cash equivalents	$	3,163	$	0	$	0	$	3,163	Cash equivalents	$	2,415	$	—	$	—	$	2,415
Fixed maturity securities, available-for-sale:	Fixed maturity securities, available-for-sale:									Fixed maturity securities, available-for-sale:
United States Government securities	United States Government securities	0		774		0		774		United States Government securities	—		1,432		—		1,432
Government sponsored securities	Government sponsored securities	0		69		0		69		Government sponsored securities	—		68		—		68
Foreign government securities	Foreign government securities	0		305		0		305		Foreign government securities	—		347		—		347
States, municipalities and political subdivisions, tax-exempt	States, municipalities and political subdivisions, tax-exempt	0		5,579		0		5,579		States, municipalities and political subdivisions, tax-exempt	—		5,621		—		5,621
Corporate securities	Corporate securities	0		10,567		325		10,892		Corporate securities	—		12,027		336		12,363
Residential mortgage-backed securities	Residential mortgage-backed securities	0		4,343		2		4,345		Residential mortgage-backed securities	—		4,092		5		4,097
Commercial mortgage-backed securities	Commercial mortgage-backed securities	0		72		0		72		Commercial mortgage-backed securities	—		64		—		64
Other securities	Other securities	0		1,954		5		1,959		Other securities	—		2,888		19		2,907
Total fixed maturity securities, available-for-sale	Total fixed maturity securities, available-for-sale	0		23,663		332		23,995		Total fixed maturity securities, available-for-sale	—		26,539		360		26,899
Equity securities:	Equity securities:									Equity securities:
Exchange traded funds	Exchange traded funds	1,154		0		0		1,154		Exchange traded funds	1,750		—		—		1,750
Fixed maturity mutual funds		0		144		0		144

Common equity securities	Common equity securities	171		30		0		201		Common equity securities	8		34		—		42
Private equity securities	Private equity securities	0		0		60		60		Private equity securities	—		—		89		89
Total equity securities	Total equity securities	1,325		174		60		1,559		Total equity securities	1,758		34		89		1,881
Other invested assets - common equity securities										Other invested assets - common equity securities	138		—		—		138
Securities lending collateral	Securities lending collateral	0		1,199		0		1,199		Securities lending collateral	—		2,155		—		2,155
Derivatives		0		43		0		43
Derivatives - other assets										Derivatives - other assets	—		19		—		19
Total assets	Total assets	$	4,488	$	25,079	$	392	$	29,959	Total assets	$	4,311	$	28,747	$	449	$	33,507
Liabilities:	Liabilities:									Liabilities:
Derivatives		$	0	$	(5)	$	0	$	(5)
Derivatives - other liabilities										Derivatives - other liabilities	$	—	$	(1)	$	—	$	(1)
Total liabilities	Total liabilities	$	0	$	(5)	$	0	$	(5)	Total liabilities	$	—	$	(1)	$	—	$	(1)

-18-

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:


		Corporate Securities		Residential Mortgage- backed Securities		Other Securities		Equity Securities		Total			Corporate Securities		Residential Mortgage- backed Securities		Other Securities		Equity Securities		Total
Three Months Ended March 31, 2022												Three Months Ended March 31, 2022
Beginning balance at January 1, 2022												Beginning balance at January 1, 2022	$	336	$	5	$	19	$	89	$	449
Total gains (losses):												Total gains (losses):
Recognized in net income												Recognized in net income	1		—		—		3		4
Recognized in accumulated other comprehensive (loss) income												Recognized in accumulated other comprehensive (loss) income	(2)		(1)		1		—		(2)
Purchases												Purchases	46		—		17		8		71
Sales												Sales	(7)		—		—		(1)		(8)
Settlements												Settlements	(33)		—		—		—		(33)

Ending balance at March 31, 2022												Ending balance at March 31, 2022	$	341	$	4	$	37	$	99	$	481
Change in unrealized gains (losses) included in net income related to assets still held at March 31, 2022												Change in unrealized gains (losses) included in net income related to assets still held at March 31, 2022	$	—	$	—	$	—	$	3	$	3

Three Months Ended March 31, 2021	Three Months Ended March 31, 2021											Three Months Ended March 31, 2021
Beginning balance at January 1, 2021	Beginning balance at January 1, 2021	$	325	$	2	$	5	$	60	$	392	Beginning balance at January 1, 2021	$	325	$	2	$	5	$	60	$	392
Total gains:	Total gains:											Total gains:
Recognized in net income	Recognized in net income	0		0		0		8		8		Recognized in net income	—		—		—		8		8
Recognized in accumulated other comprehensive loss		3		0		0		0		3
Recognized in accumulated other comprehensive (loss) income												Recognized in accumulated other comprehensive (loss) income	3		—		—		—		3
Purchases	Purchases	39		0		0		0		39		Purchases	39		—		—		—		39
Sales	Sales	(2)		0		0		(3)		(5)		Sales	(2)		—		—		(3)		(5)
Settlements	Settlements	(41)		0		0		0		(41)		Settlements	(41)		—		—		—		(41)

Ending balance at March 31, 2021	Ending balance at March 31, 2021	$	324	$	2	$	5	$	65	$	396	Ending balance at March 31, 2021	$	324	$	2	$	5	$	65	$	396
Change in unrealized losses included in net income related to assets still held at March 31, 2021		$	0	$	0	$	0	$	8	$	8

Three Months Ended March 31, 2020
Beginning balance at January 1, 2020		$	303	$	2	$	7	$	85	$	397
Total losses:
Recognized in net income		(2)		0		0		(6)		(8)
Recognized in accumulated other comprehensive loss		(10)		0		0		0		(10)
Purchases		26		0		0		12		38
Sales		(3)		0		0		(9)		(12)
Settlements		(11)		0		(2)		0		(13)
Transfers into Level III		13		0		0		0		13

Ending balance at March 31, 2020		$	316	$	2	$	5	$	82	$	405
Change in unrealized losses included in net income related to assets still held at March 31, 2020		$	0	$	0	$	0	$	(7)	$	(7)
Change in unrealized gains (losses) included in net income related to assets still held at March 31, 2021												Change in unrealized gains (losses) included in net income related to assets still held at March 31, 2021	$	—	$	—	$	—	$	8	$	8

There were no individually material transfers into or out of Level III during the three months ended March 31, ~~2021~~2022 or ~~2020.~~2021.

Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our ~~acquisition~~acquisitions of ~~Beacon on February 28, 2020.~~myNEXUS and MMM during the second quarter of 2021. The net assets acquired in our ~~acquisition~~acquisitions of ~~Beacon~~myNEXUS and MMM and resulting goodwill and other intangible assets were recorded at fair value primarily using Level III inputs. The majority of ~~Beacon’s~~ assets acquired and liabilities assumed were recorded at their carrying values as of the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in our ~~acquisition~~acquisitions of ~~Beacon~~myNEXUS and MMM were internally estimated based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our ~~acquisition~~acquisitions of ~~Beacon~~myNEXUS and MMM described above, there were no material assets or liabilities measured at fair value on a nonrecurring basis during the three months ended March 31, ~~2021~~2022 or ~~2020.~~2021.

Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices in active markets to estimate fair values for recognition and disclosure purposes.

~~-19-~~

Where quoted market prices in active markets are not available, fair values are estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.

-19-

Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted market prices obtained from the pricing services during the three months ended March 31, ~~2021~~2022 or ~~2020.~~2021.

In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated balance sheets.

Non-financial instruments such as real estate, property and equipment, other current ~~or noncurrent~~ assets, deferred income taxes, intangible assets and certain financial instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our underlying economic value.

The carrying amounts reported in the consolidated balance sheets for cash, premium receivables, self-funded receivables, other receivables, unearned income, accounts payable and accrued expenses, and certain other current liabilities approximate fair value because of the ~~short term~~short-term nature of these items. These assets and liabilities are not listed in the table below.

The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our consolidated balance sheets:

Other invested assets: Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations and mortgage loans, as well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. Mortgage loans are carried at amortized cost, which approximates fair value. The carrying value of corporate-owned life insurance policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.

Short-term borrowings: The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.

Long-term ~~debt –~~ debt—commercial paper: The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest rates at market value.

Long-term ~~debt –~~ debt—senior unsecured notes and surplus notes: The fair values of our notes are based on quoted market prices in active markets for the same or similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and remaining maturities.

Long-term ~~debt –~~ debt—convertible debentures: The fair value of our convertible debentures is based on the quoted market price in the active private market in which the convertible debentures trade.

-20-

A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at March 31, ~~2021~~2022 and December 31, ~~2020~~2021 is as follows:

Carrying
Value Estimated Fair Value
Level I Level II Level III Total
March 31, 2021
Assets:
Other invested assets $ 4,474 $ 0 $ 0 $ 4,474 $ 4,474
Liabilities:
Debt:
Notes 23,125 0 25,289 0 25,289
Convertible debentures 109 0 797 0 797
December 31, 2020
Assets:
Other invested assets $ 4,285 $ 0 $ 0 $ 4,285 $ 4,285
Liabilities:
Debt:
Commercial paper 250 0 250 0 250
Notes 19,677 0 23,307 0 23,307
Convertible debentures 108 0 712 0 712


	Carrying Value		Estimated Fair Value
			Level I		Level II		Level III		Total
March 31, 2022
Assets:
Other invested assets	$	5,239	$	—	$	—	$	5,239	$	5,239
Liabilities:
Debt:
Short-term borrowings	275		—		275		—		275

Commercial paper	525		—		525		—		525
Notes	22,354		—		23,030		—		23,030
Convertible debentures	102		—		730		—		730

December 31, 2021
Assets:
Other invested assets	$	5,087	$	—	$	—	$	5,087	$	5,087
Liabilities:
Debt:
Short-term borrowings	275		—		275		—		275
Commercial paper	300		—		300		—		300
Notes	22,384		—		25,150		—		25,150
Convertible debentures	72		—		687		—		687

8. Income Taxes

During the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, we recognized income tax expense of ~~$509~~$531 and ~~$566,~~$509, respectively, which represent effective income tax rates of ~~23.4%~~22.8% and ~~27.1%~~23.4%, respectively. The decrease in our effective ~~income~~ tax rate from the three months ended March 31, 2021 was primarily ~~due~~related to the ~~repeal~~tax impact of ~~the non-tax deductible HIP Fee effective beginning~~expected geographic changes in ~~2021.~~

our mix of 2022 earnings.

Income taxes payable totaled ~~$176~~$395 at March 31, ~~2021.~~2022. Income taxes receivable totaled ~~$262~~$173 at December 31, ~~2020.~~2021. We ~~recognize~~recognized the income tax payable as a liability under the caption “Other current liabilities” and the income tax receivable as an asset under the caption “Other current assets” in our consolidated balance sheets.

-21-

9. Medical Claims Payable

A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the three months ended March 31, ~~2021~~2022 is as follows:


		Commercial & Specialty Business		Government Business		Other		Total			Commercial & Specialty Business		Government Business		Other		Total
Gross medical claims payable, beginning of period	Gross medical claims payable, beginning of period	$	3,294	$	7,646	$	195	$	11,135	Gross medical claims payable, beginning of period	$	3,847	$	9,157	$	278	$	13,282
Ceded medical claims payable, beginning of period	Ceded medical claims payable, beginning of period	(13)		(33)		0		(46)		Ceded medical claims payable, beginning of period	(13)		(8)		—		(21)
Net medical claims payable, beginning of period	Net medical claims payable, beginning of period	3,281		7,613		195		11,089		Net medical claims payable, beginning of period	3,834		9,149		278		13,261

Business combinations and purchase adjustments										Business combinations and purchase adjustments	3		—		—		3
Net incurred medical claims:	Net incurred medical claims:									Net incurred medical claims:
Current period	Current period	6,575		17,289		351		24,215		Current period	7,070		20,586		408		28,064
Prior periods redundancies	Prior periods redundancies	(503)		(970)		(15)		(1,488)		Prior periods redundancies	(236)		(643)		(54)		(933)
Total net incurred medical claims	Total net incurred medical claims	6,072		16,319		336		22,727		Total net incurred medical claims	6,834		19,943		354		27,131
Net payments attributable to:	Net payments attributable to:									Net payments attributable to:
Current period medical claims	Current period medical claims	4,164		10,650		217		15,031		Current period medical claims	4,571		12,331		214		17,116
Prior periods medical claims	Prior periods medical claims	1,746		4,856		146		6,748		Prior periods medical claims	2,232		6,457		137		8,826
Total net payments	Total net payments	5,910		15,506		363		21,779		Total net payments	6,803		18,788		351		25,942
Net medical claims payable, end of period	Net medical claims payable, end of period	3,443		8,426		168		12,037		Net medical claims payable, end of period	3,868		10,304		281		14,453
Ceded medical claims payable, end of period	Ceded medical claims payable, end of period	9		30		0		39		Ceded medical claims payable, end of period	9		8		—		17
Gross medical claims payable, end of period	Gross medical claims payable, end of period	$	3,452	$	8,456	$	168	$	12,076	Gross medical claims payable, end of period	$	3,877	$	10,312	$	281	$	14,470

At March 31, ~~2021,~~2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business was ~~$101, $931~~$148, $1,217 and ~~$2,411~~$2,503 for the claim years ~~2019~~2020 and prior, ~~2020~~2021 and ~~2021,~~2022, respectively.

At March 31, ~~2021,~~2022, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was ~~$344, $1,442~~$270, $1,779 and ~~$6,640~~$8,255 for the claim years ~~2019~~2020 and prior, ~~2020~~2021 and ~~2021,~~2022, respectively.

At March 31, ~~2021,~~2022, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was ~~$0, $34~~$3, $84 and ~~$134~~$194 for the claim years ~~2019~~2020 and prior, ~~2020~~2021 and ~~2021,~~2022, respectively.

-22-

A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the three months ended March 31, ~~2020~~2021 is as follows:

Commercial
& Specialty
Business Government
Business Other Total
Gross medical claims payable, beginning of period $ 3,039 $ 5,608 $ 0 $ 8,647
Ceded medical claims payable, beginning of period (14) (19) 0 (33)
Net medical claims payable, beginning of period 3,025 5,589 0 8,614
Business combinations and purchase adjustments 0 141 198 339
Net incurred medical claims:
Current period 6,090 15,010 130 21,230
Prior periods redundancies (293) (407) 0 (700)
Total net incurred medical claims 5,797 14,603 130 20,530
Net payments attributable to:
Current period medical claims 3,908 9,698 138 13,744
Prior periods medical claims 1,875 4,234 0 6,109
Total net payments 5,783 13,932 138 19,853
Net medical claims payable, end of period 3,039 6,401 190 9,630
Ceded medical claims payable, end of period 37 23 0 60
Gross medical claims payable, end of period $ 3,076 $ 6,424 $ 190 $ 9,690


	Commercial & Specialty Business		Government Business		Other		Total
Gross medical claims payable, beginning of period	$	3,294	$	7,646	$	195	$	11,135
Ceded medical claims payable, beginning of period	(13)		(33)		—		(46)
Net medical claims payable, beginning of period	3,281		7,613		195		11,089

Net incurred medical claims:
Current period	6,575		17,289		351		24,215
Prior periods redundancies	(503)		(970)		(15)		(1,488)
Total net incurred medical claims	6,072		16,319		336		22,727
Net payments attributable to:
Current period medical claims	4,164		10,650		217		15,031
Prior periods medical claims	1,746		4,856		146		6,748
Total net payments	5,910		15,506		363		21,779
Net medical claims payable, end of period	3,443		8,426		168		12,037
Ceded medical claims payable, end of period	9		30		—		39
Gross medical claims payable, end of period	$	3,452	$	8,456	$	168	$	12,076

The favorable development recognized in the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 resulted primarily from trend factors in late ~~2020~~2021 and late ~~2019,~~2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 2020 ~~and 2019~~ developing faster than expected also contributed to the ~~favorability.~~favorable development in the three months ended March 31, 2021. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at March 31, 2022.

The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 2022 and 2021 is as follows:


		Three Months Ended				Three Months Ended
		March 31, 2021		March 31, 2020			March 31, 2022				March 31, 2021

Net incurred medical claims:	Net incurred medical claims:							Net incurred medical claims:
Commercial & Specialty Business	Commercial & Specialty Business	$	6,072	$	5,797			Commercial & Specialty Business	$	6,834		$	6,072
Government Business	Government Business	16,319		14,603				Government Business	19,943			16,319
Other	Other	336		130				Other	354			336
Total net incurred medical claims	Total net incurred medical claims	22,727		20,530				Total net incurred medical claims	27,131			22,727
Quality improvement and other claims expense	Quality improvement and other claims expense	972		959				Quality improvement and other claims expense	1,084			972
Benefit expense	Benefit expense	$	23,699	$	21,489			Benefit expense	$	28,215		$	23,699

-23-

The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the consolidated balance sheet, as of March 31, ~~2021,~~2022, is as follows:

Commercial
& Specialty
Business Government
Business Other Total
Net medical claims payable, end of period $ 3,443 $ 8,426 $ 168 $ 12,037
Ceded medical claims payable, end of period 9 30 0 39
Insurance lines other than short duration 0 271 0 271
Gross medical claims payable, end of period $ 3,452 $ 8,727 $ 168 $ 12,347


	Commercial & Specialty Business		Government Business		Other		Total
Net medical claims payable, end of period	$	3,868	$	10,304	$	281	$	14,453
Ceded medical claims payable, end of period	9		8		—		17
Insurance lines other than short duration	—		243		—		243
Gross medical claims payable, end of period	$	3,877	$	10,555	$	281	$	14,713

10. Debt

We generally issue senior unsecured notes for long-term borrowing purposes. At March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, we had ~~$23,100~~$22,329 and ~~$19,652,~~$22,359, respectively, outstanding under these notes.

On April 15, 2021, we provided notice to the holders of our outstanding 3.700% Notes due August 15, 2021 that we will be redeeming the $700 outstanding principal balance of such notes on May 15, 2021 at a redemption price equal to 100% of the aggregate principal amount of the notes being redeemed, plus accrued and unpaid interest.

On March 17, 2021, we issued $500 aggregate principal amount of 0.450% Notes due 2023 (the “2023 Notes”), $750 aggregate principal amount of 1.500% Notes due 2026 (the “2026 Notes”), $1,000 aggregate principal amount of 2.550% Notes due 2031 (the “2031 Notes”) and $1,250 aggregate principal amount of 3.600% Notes due 2051 (the “2051 Notes”) under our shelf registration statement. Interest on the 2023 Notes, 2026 Notes, 2031 Notes and 2051 Notes is payable semi-annually in arrears on March 15 and September 15 of each year, commencing September 15, 2021. We intend to use the net proceeds for working capital and general corporate purposes, including, but not limited to, the funding of acquisitions, repayment of short-term and long-term debt and the repurchase of our common stock pursuant to our share repurchase program.

We have an unsecured surplus note with an outstanding principal balance of $25 at both March 31, ~~2021~~2022 and December 31, ~~2020.~~2021.

We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. ~~The~~On April 18, 2022, we amended and restated the credit agreement for the 5-Year Facility ~~provides~~to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit upavailable under the 5-Year Facility from $2,500 to ~~$2,500~~$4,000. Also on April 18, 2022, concurrently with the amendment and ~~matures in June 2024. We also have a~~restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility (“that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 (the “2021 364-Day Facility” and together with the 5-Year Facility, the “Credit Facilities”). In June 2021, we terminated our 364-day senior revolving credit facility (the “prior 364-Day Facility”), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate ~~purposes, which provides for credit in the amount of $1,000 and matures in June 2021.~~purposes. Our ability to borrow under ~~these credit facilities~~the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the ~~applicable~~ credit ~~agreement.~~agreement for the 5-Year Facility. As of March 31, ~~2021,~~2022, our debt-to-capital ratio, as defined and calculated under the ~~credit facilities,~~Credit Facilities, was ~~40.7%~~39.2%. We do not believe the restrictions contained in ~~any of~~ our ~~credit facility~~5-Year Facility covenants materially affect our financial or operating flexibility. As of March 31, ~~2021,~~2022, we were in compliance with all of ~~the~~our debt covenants under ~~these credit facilities.~~the Credit Facilities. There were no amounts outstanding under the 5-Year Facility, 2021 364-Day Facility or the prior 364-Day Facility at any time during the three months ended March 31, ~~2021~~2022 or the year ended December 31, ~~2020. At March 31, 2021 and December 31, 2020, there were no amounts outstanding under our 5-Year Facility.~~2021.

Through certain subsidiaries, we have entered into multiple 364-day lines of credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to ~~$300.~~$200. At March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, there were no amounts outstanding under our Subsidiary Credit Facilities.

We have an authorized commercial paper program of up to $3,500, the proceeds of which may be used for general corporate purposes. At March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, we had $0$525 and ~~$250,~~$300, respectively, outstanding under this program.

We have outstanding senior unsecured convertible debentures due 2042 (the “Debentures”), which are governed by an indenture (the “indenture”) between us and The Bank of New York Mellon Trust Company, N.A., as trustee. We ~~have~~

~~-24-~~

accounted for the Debentures in accordance with the FASB cash conversion guidance for debt with conversion and other ~~options.~~options at the time of issue. As a result, the value of the embedded conversion option (net of deferred taxes and equity issuance costs) ~~has been~~was bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets. We adopted ASU 2020-06 on January 1, 2022 using the modified retrospective transition method, which resulted in an increase to our reported debt outstanding of $31, a decrease of our deferred tax liabilities of $8 and a corresponding cumulative-effect reduction to our opening retained earnings of $23, eliminating the bifurcation of the embedded conversion option. During the three months ended March 31, 2022, $2 of aggregate principal amount of the Debentures was surrendered for conversion by certain holders in accordance with the terms and provisions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the three months ended March 31, 2022 of $14.

-24-

The following table summarizes at March 31, ~~2021~~2022 the related balances, conversion rate and conversion price of the Debentures:


Outstanding principal amount	$	~~159~~102
~~Unamortized debt discount~~	$	49
Net debt carrying amount	$	~~109~~102
~~Equity component carrying amount~~	$	58
Conversion rate (shares of common stock per $1,000 of principal amount)	~~14.1158~~14.2390
Effective conversion price (per $1,000 of principal amount)	$	~~70.8426~~70.2297

We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York (collectively, the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had no$275 of outstanding short-term borrowings from the FHLBs at each of March 31, ~~2021~~2022 and December 31, ~~2020.~~2021.

All debt is a direct obligation of Anthem, Inc., except for the surplus note, the FHLB borrowings, and the Subsidiary Credit Facilities.

11. Commitments and Contingencies

Litigation and Regulatory Proceedings

In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we have meritorious defenses.

Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.

With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented, (ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of established reserves is, in the aggregate, from $0 to approximately $250 at March 31, ~~2021.~~2022. This estimated aggregate range of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be made.

Blue Cross Blue Shield Antitrust Litigation

We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the “Blue plans”) across the country. Cases filed in twenty-eight states were consolidated into a single,

~~-25-~~

multi-district proceeding captioned In re Blue Cross Blue Shield Antitrust Litigation that is pending in the ~~United States~~U.S. District Court for the Northern District of Alabama (the “Court”). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts

-25-

programs and other arrangements in violation of the Sherman Antitrust Act (“Sherman Act”) and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.

In ~~response to~~April 2018, the Court issued an order on the parties’ cross motions for partial summary judgment, ~~by plaintiffs and defendants, the Court issued an order in April 2018~~ determining that the defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. The Court also found that there remain genuine issues of material fact as to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks. In April 2019, the plaintiffs filed motions for class certification, ~~in conjunction with their supporting expert reports, and the~~which defendants ~~filed motions to exclude plaintiffs’ experts, and to oppose plaintiffs’ motions for class certification.~~opposed.

The BCBSA and Blue plans have approved a settlement agreement and release (the “Subscriber Settlement Agreement”) with the subscriber plaintiffs. If approved by the Court, the Subscriber Settlement Agreement will require the defendants to make a monetary settlement payment, our portion of which is estimated to be $594, and will contain certain terms imposing non-monetary ~~terms~~obligations including (i) eliminating the “national best efforts” rule in the BCBSA license agreements (which rule limits the percentage of non-Blue revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan. As of March 31, ~~2021,~~2022, the liability balance accrued for our estimated ~~remaining~~ payment obligation was $507, net of payments made.

OnIn November ~~30,~~ 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. All terms of the Subscriber Settlement Agreement are subject to final approval by the ~~Court before they become effective. Objections~~Court. The deadline for objections to the settlement as well as the deadline for those who wish to opt-out from the settlement was in July 2021 and a small number of subscribers submitted valid opt outs by the deadline. The claims deadline was in November 2021 and in excess of 8000 claims were submitted. A final approval hearing was held in October 2021. The Court took the request for approval under advisement and requested supplemental briefing that was submitted. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members. The notice process was completed in March 2022. Objections to the supplemental notice along with opt-outs must be submitted by ~~July 28, 2021. Claims must be filed~~May 2, 2022, with a motion certifying compliance with the supplemental notice due from class counsel by ~~November 5, 2021. A final approval hearing has been scheduled for October 20, 2021.~~ May 10, 2022. If the Court grants approval of the Subscriber Settlement Agreement, and after all appellate rights have expired or have been exhausted in a manner that affirms the Court’s final order and judgment, the defendants’ payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective.

InIn October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, ~~and~~which defendants ~~filed an opposition to that motion.~~opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until ~~after a ruling on~~the Court determines the standard of review applicable to providers’ claims. ~~Standard~~In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions, which are now fully briefed. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued (1) an order granting certain defendants’ motion for partial summary judgment against provider plaintiffs who had previously released claims against such defendants, and (2) an order granting provider plaintiffs’ motion for partial summary judgment, holding that Ohio v. American Express Co. does not affect the ~~provider litigation are due on May 21, 2021, and certain other potentially dispositive motions on issues~~standard of ~~liability are due on June 18, 2021.~~review in this case. We intend to continue to vigorously defend the provider ~~suit;~~suit, which we believe is without merit; however, its ultimate outcome cannot be presently determined.

Blue Cross of California Taxation Litigation

In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross) (“BCC”) was named as a defendant in a California taxpayer action filed in Los Angeles County Superior Court (the “Superior Court”) captioned Michael D. Myers v. State Board of Equalization, et al. This action was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, is an “insurer” for purposes of taxation despite acknowledging it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax (“GPT”) calculated as 2.35% on gross premiums. As a licensed Health Care Service Plan, BCC has paid the California Corporate Franchise Tax (“CFT”), the tax paid by California businesses generally. Plaintiff contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing

-26-

agencies to collect the GPT and an order requiring BCC to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.

~~-26-~~

Because the GPT is constitutionally imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax periods at issue in the litigation.

In March 2018, the Superior Court denied BCC's motion for judgment on the pleadings and similar motions brought by other entities. BCC filed a motion for summary judgment with the Superior Court, which was heard in October 2020. In December 2020, the Superior Court granted ~~BCC's~~BCC’s motion for summary judgment, dismissing the plaintiff's lawsuit. ~~Plaintiff has~~In November 2021, the plaintiff appealed the order granting our motion for summary judgment. Our responding brief was filed in February 2022. We estimate that the appeal will be heard sometime in 2022. We intend to vigorously defend the appeal of this lawsuit.

Express Scripts, Inc. Pharmacy Benefit Management Litigation

In March 2016, we filed a lawsuit against Express Scripts, Inc. (“Express Scripts”), our vendor at the time for PBM services, captioned Anthem, Inc. v. Express Scripts, Inc., in the U.S. District Court for the Southern District of New York. The lawsuit seeks to recover over $14,800 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the “ESI PBM Agreement”), over $158 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.

Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we have been unjustly enriched by its payment of $4,675 at the time we entered into the ESI PBM Agreement. In March 2017, the ~~court~~District Court granted our motion to dismiss Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. ~~The~~After such action, the only remaining claims ~~are~~were for breach of contract and declaratory relief. ~~Rebuttal expert reports were submitted~~In August 2021, Express Scripts filed a motion for summary judgment, which we opposed. In March 2022, the District Court granted in ~~October 2020~~part and ~~discovery must be completed by June 2021.~~denied in part Express Scripts' motion for summary judgment. The District Court dismissed our declaratory judgment claim, our breach of contract claim for failure to prove damages and most of our operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Quarterly Report on Form 10-Q are (i) our operational breach claim based on Express Scripts' prior authorization processes and (ii) Express Scripts' counterclaim for breach of the market check provision of the ESI PBM Agreement. We intend to appeal the decision at the appropriate time, vigorously pursue our claims and defend against ~~any~~ counterclaims, which we believe are without merit; however, the ultimate outcome cannot be presently determined.

In re Express Scripts/Anthem ERISA Litigation

We are a defendant in a class action lawsuit that was initially filed in June 2016 against Anthem, Inc. and Express Scripts, which has been consolidated into a single multi-district lawsuit captioned In Re Express Scripts/Anthem ERISA Litigation, in the U.S. District Court for the Southern District of New York. The consolidated complaint was filed by plaintiffs against Express Scripts and us on behalf of all persons who are participants in or beneficiaries of any ERISA or non-ERISA healthcare plan from December 1, 2009 to December 31, 2019 in which we provided prescription drug benefits through the ESI PBM Agreement and paid a percentage based co-insurance payment in the course of using that prescription drug benefit. The plaintiffs allege that we breached our duties, either under ERISA or with respect to the implied covenant of good faith and fair dealing implied in the health plans, (i) by failing to adequately monitor Express Scripts’ pricing under the ESI PBM Agreement, (ii) by placing our own pecuniary interest above the best interests of our insureds by allegedly agreeing to higher pricing in the ESI PBM Agreement in exchange for the purchase price for our NextRx PBM business, and (iii) with

-27-

respect to the non-ERISA members, by negotiating and entering into the ESI PBM Agreement that was allegedly detrimental to the interests of such non-ERISA members. Plaintiffs seek to hold us and Express Scripts jointly and severally liable and to recover all losses suffered by the proposed class, equitable relief, disgorgement of alleged ill-gotten gains, injunctive relief, attorney’s fees and costs and interest.

In April 2017, we filed a motion to dismiss the claims brought against us, and it was granted, without prejudice, in January 2018. Plaintiffs ~~filed a notice of~~pursued an appeal with the United States Court of Appeals for the Second Circuit (the “Second Circuit”)~~, which was heard in October 2018.~~. In December 2020, the Second Circuit affirmed the trial ~~court's decision~~court’s order dismissing the ERISA complaint. Plaintiffs filed a Petition for Rehearing and Rehearing En ~~Banc. Plaintiff’s Petition for~~

~~-27-~~

~~Rehearing~~Banc, which was denied. Plaintiffs ~~have until June 2021 to file~~filed a ~~Writ~~writ of ~~Certiorari~~certiorari with the ~~U.S.~~United States Supreme ~~Court.~~Court, which we opposed. In December 2021, the United States Supreme Court requested that the Solicitor General submit a brief “expressing the views of the United States” as to whether the court should grant plaintiffs’ writ. We intend to vigorously defend this ~~suit;~~suit, which we believe is without merit; however, its ultimate outcome cannot be presently determined.

~~Cigna Corporation Merger Litigation~~

In July 2015, we and Cigna Corporation (“Cigna”) announced that we entered into the Cigna Agreement and Plan of Merger (“Cigna Merger Agreement”) pursuant to which we would acquire all outstanding shares of Cigna. In July 2016, the U.S. Department of Justice (“DOJ”) along with certain state attorneys general, filed a civil antitrust lawsuit in the U.S. District Court for the District of Columbia (“District Court”) seeking to block the merger. In February 2017, Cigna purported to terminate the Cigna Merger Agreement and commenced litigation against us in the Delaware Court of Chancery (“Delaware Court”) seeking damages, including the $1,850 termination fee pursuant to the terms of the Cigna Merger Agreement, and a declaratory judgment that its purported termination of the Cigna Merger Agreement was lawful, among other claims, which is captioned ~~Cigna Corp. v. Anthem Inc.~~

Also in February 2017, we initiated our own litigation against Cigna in the Delaware Court seeking a temporary restraining order to enjoin Cigna from terminating the Cigna Merger Agreement, specific performance compelling Cigna to comply with the Cigna Merger Agreement and damages, which is captioned ~~Anthem Inc. v. Cigna Corp~~. In April 2017, the U.S. Circuit Court of Appeals for the District of Columbia affirmed the ruling of the District Court, which blocked the merger. In May 2017, after the Delaware Court denied our motion to enjoin Cigna from terminating the Cigna Merger Agreement, we delivered to Cigna a notice terminating the Cigna Merger Agreement.

In the Delaware Court litigation, trial commenced in late February 2019 and concluded in March 2019. The Delaware Court held closing arguments in November 2019 and took the matter under consideration. In August 2020, the Delaware Court issued an opinion finding that neither party was owed damages and that we did not owe Cigna the $1,850 termination fee. The Delaware Court issued an order implementing its opinion in October 2020. Cigna filed its notice of appeal in November 2020 challenging the Court's decision that Anthem did not owe Cigna a termination fee. Cigna filed its appellate brief in December 2020, and we filed our response in January 2021. Oral argument before the Delaware Supreme Court was held in April 2021. The matter was taken under advisement. We believe Cigna’s allegations are without merit and we intend to vigorously defend against Cigna’s allegations; however, the ultimate outcome of the appeal of this litigation with Cigna cannot be presently determined.

~~In October 2018, a shareholder filed a derivative lawsuit in the State of Indiana Marion County Superior Court, captioned~~ ~~Henry Bittmann, Derivatively, et al. v. Joseph R Swedish, et al.~~, purportedly on behalf of us and our shareholders against certain current and former directors and officers alleging breaches of fiduciary duties, unjust enrichment and corporate waste associated with the Cigna Merger Agreement. This case has been stayed at the request of the parties pending the outcome of our litigation with Cigna in the Delaware Court. This lawsuit’s ultimate outcome cannot be presently determined.

Medicare Risk Adjustment Litigation

In March 2020, the ~~DOJ~~U.S. Department of Justice (“DOJ”) filed a civil lawsuit against Anthem, Inc. in the U.S. District Court for the Southern District of New York in a case captioned United States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for Medicare and Medicaid Services (“CMS”) for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its allegations. In September 2020, we filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. The motions are fully briefed and no decision has been rendered. We intend to continue to vigorously defend this ~~suit;~~suit, which we believe is without merit; however, the ultimate outcome cannot be presently determined.

Investigations of CareMore and HealthSun

With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices involving data submitted to CMS (unrelated to our retrospective chart review program) at CareMore Health Plans, Inc. (“CareMore”), one of

~~-28-~~

our California subsidiaries, and HealthSun Health Plans, Inc. (“HealthSun”), one of our Florida subsidiaries. Our CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our HealthSun investigation ~~focuses~~has focused on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-disclosed the existence of both of our investigations to CMS and the Criminal ~~Division~~and Civil Divisions of the ~~DOJ, which then initiated an investigation.~~DOJ. We are cooperating with the ~~government's~~ongoing investigations of the Criminal and Civil Divisions of the DOJ related to these risk adjustment practices, and have entered into a tolling agreement with the Civil Division of the DOJ related to its investigation. We are ~~in the process of~~ analyzing the scope of potential data corrections to be submitted to CMS and have begun to submit data corrections to CMS. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare and financial representation provisions, based on the conduct discovered during our investigation. ~~We are in active litigation with two groups of sellers regarding part~~While certain elements of the ~~escrowed funds~~escrow claims were resolved in ~~cases captioned~~ ~~Shareholder Representative Services, LLC v. ATH Holding Company, LLC and Highland Acquisition Holdings, LLC~~ ~~and~~ ~~LPPAS Representative, LLC v. ATH Holding Company, LLC,~~ ~~both pending~~the fourth quarter of 2021, there remains litigation in the Delaware ~~Court.~~

Court of Chancery related to the remaining indemnity claims for escrowed funds.

Other Contingencies

From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. We, like ~~HMOs~~Health Maintenance Organizations (“HMOs”) and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, ~~PPO~~Preferred Provider Organizations and other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.

-28-

In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, and are from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.

Contractual Obligations and Commitments

In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those agreements. Our remaining commitment under this agreement at March 31, ~~2021~~2022 is approximately ~~$1,223.~~$971. We will have the ability to terminate the agreement upon the occurrence of certain events, subject to early termination fees.

~~Beginning in~~In the second quarter of 2019, we began using our pharmacy benefits manager IngenioRx to market and offer PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. The comprehensive ~~prescription benefits management~~PBM services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities. IngenioRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.

12. Capital Stock

Use of Capital – Dividends and Stock Repurchase Program

We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.

~~-29-~~

A summary of our cash dividend activity for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:

Declaration Date

Record Date

Payment Date

Cash

Dividend

per Share

Total

Declaration Date

Record Date

Payment Date

Cash

Dividend

per Share

Total

Three Months Ended March 31, 2022

January 25, 2022

March 10, 2022

March 25, 2022

$1.28

309

Three Months Ended March 31, 2021

January 26, 2021

March 10, 2021

March 25, 2021

$1.13

277

January 26, 2021

March 10, 2021

March 25, 2021

$1.13

277

Three Months Ended March 31, 2020

January 28, 2020

March 16, 2020

March 27, 2020

$0.95

240

On April ~~20, 2021,~~19, 2022, our Audit Committee declared a second quarter ~~2021~~2022 dividend to shareholders of ~~$1.13~~$1.28 per share, payable on June ~~25, 2021~~24, 2022 to shareholders of record at the close of business on June 10, ~~2021.~~2022.

Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On January 26, 2021, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized a $5,000 increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of

-29-

capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.

A summary of common stock repurchases for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:


		Three Months Ended March 31					Three Months Ended March 31
		2021		2020			2022		2021
Shares repurchased	Shares repurchased	1.4		1.9		Shares repurchased	1.2		1.4
Average price per share	Average price per share	$	316.06	$	275.38	Average price per share	$	453.32	$	316.06
Aggregate cost	Aggregate cost	$	447	$	529	Aggregate cost	$	545	$	447
Authorization remaining at the end of the period	Authorization remaining at the end of the period	$	5,645	$	3,263	Authorization remaining at the end of the period	$	3,647	$	5,645

For additional information regarding the use of capital for debt security repurchases, see Note 10, ~~“Debt”,~~“Debt,” included in this Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, ~~2020~~2021 included in our ~~2020~~2021 Annual Report on Form 10-K.

Stock Incentive Plans

A summary of stock option activity for the three months ended March 31, ~~2021~~2022 is as follows:

Number of
Shares Weighted-
Average
Option Price
per Share Weighted-
Average
Remaining
Contractual
Life (Years) Aggregate
Intrinsic
Value
Outstanding at January 1, 2021 3.1 $ 230.00
Granted 0.7 311.47
Exercised (0.4) 185.63
Forfeited or expired 0 277.15
Outstanding at March 31, 2021 3.4 251.80 7.44 $ 361
Exercisable at March 31, 2021 1.8 214.76 6.16 $ 259

~~-30-~~


	Number of Shares	Weighted- Average Option Price per Share		Weighted- Average Remaining Contractual Life (Years)	Aggregate Intrinsic Value
Outstanding at January 1, 2022	2.9	$	255.50
Granted	0.5	451.50
Exercised	(0.2)	249.89
Forfeited or expired	—	306.80
Outstanding at March 31, 2022	3.2	288.98		7.06	$	643
Exercisable at March 31, 2022	1.9	238.19		5.87	$	480

A summary of the status of nonvested restricted stock activity, including restricted stock units and performance units, for the three months ended March 31, ~~2021~~2022 is as follows:


		Restricted Stock Shares and Units	Weighted- Average Grant Date Fair Value per Share			Restricted Stock Shares and Units	Weighted- Average Grant Date Fair Value per Share
Nonvested at January 1, 2021		1.3	$	272.51
Nonvested at January 1, 2022					Nonvested at January 1, 2022	1.3	$	299.65
Granted	Granted	0.9	311.32		Granted	0.5	451.42
Vested	Vested	(0.8)	244.20		Vested	(0.5)	301.42
Forfeited	Forfeited	0	279.37		Forfeited	—	310.98
Nonvested at March 31, 2021		1.4	294.70
Nonvested at March 31, 2022					Nonvested at March 31, 2022	1.3	353.20

During the three months ended March 31, ~~2021,~~2022, we granted approximately ~~0.3~~0.2 restricted stock units that are contingent upon us achieving earnings targets over the three year period from ~~2021~~2022 to ~~2023.~~2024. These grants have been included in the activity shown above, but will be subject to adjustment at the end of ~~2023~~2024 based on results in the three year period.

During the three months ended March 31, 2021, we granted an additional 0.3 restricted stock units associated with our 2018 grants that were earned as a result of satisfactory completion of performance measures between 2018 and 2020. These grants and vested shares have been included in the activity shown above.

Fair Value

We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair value methodology, see Note 15, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended December 31, ~~2020~~2021 included in our ~~2020~~2021 Annual Report on Form 10-K.

-30-

The following weighted-average assumptions were used to estimate the fair values of options granted during the three months ended March 31, ~~2021~~2022 and ~~2020:~~2021:


		Three Months Ended March 31					Three Months Ended March 31
		2021		2020			2022		2021
Risk-free interest rate	Risk-free interest rate	1.44	%	1.30	%	Risk-free interest rate	1.97	%	1.44	%
Volatility factor	Volatility factor	30.00	%	26.00	%	Volatility factor	29.00	%	30.00	%
Quarterly dividend yield	Quarterly dividend yield	0.360	%	0.350	%	Quarterly dividend yield	0.282	%	0.360	%
Weighted-average expected life (years)	Weighted-average expected life (years)	5.50		4.30		Weighted-average expected life (years)	5.10		5.50

The following weighted-average fair values per option or share were determined for the three months ended March 31, ~~2021~~2022 and ~~2020:~~2021:


		Three Months Ended March 31					Three Months Ended March 31
		2021		2020			2022		2021
Options granted during the period	Options granted during the period	$	79.03	$	54.03	Options granted during the period	$	116.64	$	79.03
Restricted stock awards granted during the period	Restricted stock awards granted during the period	311.32		272.03		Restricted stock awards granted during the period	451.42		311.32

-31-

13. Accumulated Other Comprehensive Loss

A reconciliation of the components of accumulated other comprehensive loss at March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:

March 31
2021 2020
Investments:
Gross unrealized gains $ 956 $ 510
Gross unrealized losses (179) (729)
Net pre-tax unrealized gains (losses) 777 (219)
Deferred tax (liability) asset (186) 51
Adjustment for noncontrolling interest (2) 0
Net unrealized gains (losses) on investments 589 (168)
Non-credit components of impairments on investments:
Gross unrealized losses (1) (44)
Deferred tax asset 0 10
Net unrealized non-credit component of impairments on investments (1) (34)
Cash flow hedges:
Gross unrealized losses (311) (327)
Deferred tax asset 65 68
Net unrealized losses on cash flow hedges (246) (259)
Defined benefit pension plans:
Deferred net actuarial loss (734) (724)
Deferred prior service credits (1) 0
Deferred tax asset 186 185
Net unrecognized periodic benefit costs for defined benefit pension plans (549) (539)
Postretirement benefit plans:
Deferred net actuarial loss (2) (25)
Deferred prior service costs 11 18
Deferred tax (liability) asset (2) 2
Net unrecognized periodic benefit credit (costs) for postretirement benefit plans 7 (5)
Foreign currency translation adjustments:
Gross unrealized gains (losses) 6 (4)
Deferred tax (liability) asset (1) 1
Net unrealized gains (losses) on foreign currency translation adjustments 5 (3)
Accumulated other comprehensive loss $ (195) $ (1,008)


	March 31
	2022		2021
Net unrealized investment (losses) gains:
Beginning of period balance	$	494	$	949
Other comprehensive loss before reclassifications, net of tax benefit of $355 and $108, respectively	(1,146)		(333)
Amounts reclassified from accumulated other comprehensive loss, net of tax (expense) benefit of $(21) and $8, respectively	77		(29)
Other comprehensive loss	(1,069)		(362)
Other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(2) and $(1), respectively	5		2
End of period balance	(570)		589

Non-credit components of impairments on investments:
Beginning of period balance	—		(2)
Other comprehensive (loss) income, net of tax benefit (expense) of $1 and $(1), respectively	(1)		1
End of period balance	(1)		(1)

Net cash flow hedges:
Beginning of period balance	(239)		(250)
Other comprehensive income, net of tax expense of $(1) and $(1), respectively	3		4
End of period balance	(236)		(246)

Pension and other postretirement benefits:
Beginning of period balance	(429)		(552)
Other comprehensive income, net of tax expense of $(2) and $(4), respectively	7		10
End of period balance	(422)		(542)

Foreign currency translation adjustments:
Beginning of period balance	(4)		5
Other comprehensive loss, net of tax benefit of $1 and $0	(3)		—
End of period balance	(7)		5

Total:
Total beginning of period accumulated other comprehensive (loss) income	(178)		150
Total other comprehensive loss, net of tax benefit of $333 and $110, respectively	(1,063)		(347)
Total other comprehensive loss attributable to noncontrolling interests, net of tax benefit of $(2) and $(1), respectively	5		2
Total end of period accumulated other comprehensive loss	$	(1,236)	$	(195)

-32-

~~Other comprehensive income (loss) reclassification adjustments for the three months ended March 31, 2021 and 2020 are as follows:~~

Three Months Ended March 31
2021 2020
Investments:
Net holding loss on investment securities arising during the period, net of tax benefit of $108 and $213, respectively $ (332) $ (716)
Reclassification adjustment for net realized (loss) gains on investment securities, net of tax expense (benefit) of $8 and ($7), respectively (28) 27
Total reclassification adjustment on investments (360) (689)
Non-credit component of impairments on investments:
Non-credit component of impairments on investments, net of tax (expense) benefit of ($1) and $9, respectively 1 (32)
Cash flow hedges:
Holding gain, net of tax expense of ($1) and ($1), respectively 4 3
Other:
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net of tax expense of ($4) and ($3), respectively 10 7
Foreign currency translation adjustment, net of tax expense of ($0) and ($0), respectively 0 (1)
Net loss recognized in other shareholders' comprehensive income, net of tax benefit of $110 and $211, respectively (345) (712)
Net loss related to noncontrolling interests, net of tax benefit of $1 and $0, respectively (2) 0
Net loss recognized in other comprehensive income, net of tax benefit of $111 and $211, respectively $ (347) $ (712)

14. Earnings per Share

The denominator for basic and diluted earnings per share for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:


		Three Months Ended March 31		Three Months Ended March 31
		2021	2020			2022	2021
Denominator for basic earnings per share – weighted-average shares	Denominator for basic earnings per share – weighted-average shares	245.0	252.4		Denominator for basic earnings per share – weighted-average shares	241.4	245.0
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures	Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures	3.2	4.0		Effect of dilutive securities – employee stock options, nonvested restricted stock awards and convertible debentures	3.0	3.2
Denominator for diluted earnings per share	Denominator for diluted earnings per share	248.2	256.4		Denominator for diluted earnings per share	244.4	248.2

During the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, weighted-average shares related to certain stock options of ~~0.4~~0.2 and ~~0.9,~~0.4, respectively, were excluded from the denominator for diluted earnings per share because the stock options were anti-dilutive.

During the three months ended March 31, 2022, we issued approximately 0.5 restricted stock units under our stock incentive plans, 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2022 through 2024. During the three months ended March 31, 2021, we issued approximately 0.9 restricted stock units under our stock incentive plans, 0.3 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2021 through 2023. During the three months ended March 31, 2020, we issued approximately 1.2 restricted stock units under our stock incentive plans, 0.2 of which vesting is contingent upon us meeting specified annual earnings targets for the three year period of 2020 through 2022. The contingent restricted stock units have been excluded from the ~~denominator~~denominators for diluted earnings per share and will be included only if and when the contingency is met.

~~-33-~~

15. Segment Information

The results of our operations are described through 4 reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other.

Our Commercial & Specialty Business segment offers plans and services to our Individual, Group risk-based, Group fee-based ~~BlueCard,~~ and ~~Specialty customers.~~BlueCard® members. The Commercial & Specialty Business segment offers health products on a full-risk basis; provides a broad array of administrative managed care services to our fee-based customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services;customers; and provides ~~an array~~a variety of specialty and other insurance products and services such as dental, vision, life, disability and ~~disability~~supplemental health insurance benefits.

Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, ~~(“NGS”),~~ and services provided to the federal government in connection with the FEHB program. Our Medicare business includes services such as Medicare Supplement plans; Medicare Advantage, including Special Needs Plans; Medicare Part D; and dual-eligible programs through Medicare-Medicaid Plans. Medicare Advantage membership also includes Medicare Advantage members in our Group Retiree Solutions business who are retired members of Commercial accounts or retired members of groups who are not affiliated with our Commercial accounts who have selected a Medicare Advantage product through us. Our Medicaid business includes our managed care alternatives through publicly funded healthcare programs, including Medicaid, Medicaid expansion programs related to the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended, Temporary Assistance for Needy Families programs, programs for seniors and people with disabilities, Children’s Health Insurance Programs, and specialty programs such as those focused on long-term services and support, HIV/AIDS, foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities or developmental disabilities. NGS acts as a Medicare contractor for the federal government in several regions across the nation.

Our IngenioRx segment includes our PBM ~~business, which began its operations during the second quarter of 2019.~~business. IngenioRx markets and offers PBM services to our affiliated health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services and mail order capabilities.

Our Other segment includes our Diversified Business Group, ~~(“DBG”),~~ which is our ~~integrated~~ health services business focused on lowering the cost and improving the quality of healthcare by enabling and creating new care delivery and payment models, with a special emphasis on serving those with complex and chronic conditions. This segment also includes certain eliminations and corporate expenses not allocated to our other reportable segments.

We define operating revenues to include premium income, product revenue and administrative fees and other revenues. Operating revenues are derived from premium and fees received, primarily from the sale and administration of health benefits and pharmacy products and services. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense.

Affiliated revenues represent revenues or cost for services provided to our subsidiaries by IngenioRx and ~~DBG to~~ our ~~subsidiaries,~~Diversified Business Group, as well as certain back-office services provided by our international businesses, and are recorded at cost or management’s estimate of fair market ~~value, and~~value. These affiliated revenues are eliminated in consolidation.

-33-

Financial data by reportable segment for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:

Commercial
& Specialty
Business Government
Business IngenioRx Other Eliminations Total
Three Months Ended March 31, 2021
Operating revenue - unaffiliated $ 9,491 $ 19,283 $ 2,738 $ 586 $ — $ 32,098
Operating revenue - affiliated — — 3,124 1,784 (4,908) 0
Operating gain 1,268 478 407 8 — 2,161
Three Months Ended March 31, 2020
Operating revenue - unaffiliated $ 9,361 $ 17,466 $ 2,344 $ 277 $ — $ 29,448
Operating revenue - affiliated 0 0 2,853 750 (3,603) 0
Operating gain 1,420 411 349 14 — 2,194

~~-34-~~


	Commercial & Specialty Business		Government Business		IngenioRx		Other		Eliminations		Total
Three Months Ended March 31, 2022
Operating revenue - unaffiliated	$	10,269	$	23,758	$	3,301	$	558	$	—	$	37,886
Operating revenue - affiliated	—		—		3,382		2,663		(6,045)		—
Operating gain	1,082		789		398		178		—		2,447
Three Months Ended March 31, 2021
Operating revenue - unaffiliated	$	9,491	$	19,283	$	2,738	$	586	$	—	$	32,098
Operating revenue - affiliated	—		—		3,124		1,784		(4,908)		—
Operating gain	1,268		478		407		8		—		2,161

The major product revenues for each of the reportable segments for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 are as follows:


		Three Months Ended March 31				Three Months Ended March 31
		2021		2020				2022		2021
Commercial & Specialty Business	Commercial & Specialty Business						Commercial & Specialty Business
Managed care products	Managed care products	$	7,689	$	7,569		Managed care products	$	8,401	$	7,689
Managed care services	Managed care services	1,386		1,381			Managed care services	1,476		1,386
Dental/Vision products and services	Dental/Vision products and services	336		315			Dental/Vision products and services	356		336
Other	Other	80		96			Other	36		80
Total Commercial & Specialty Business	Total Commercial & Specialty Business	9,491		9,361			Total Commercial & Specialty Business	10,269		9,491
Government Business	Government Business						Government Business
Managed care products	Managed care products	19,182		17,375			Managed care products	23,635		19,182
Managed care services	Managed care services	101		91			Managed care services	123		101
Total Government Business	Total Government Business	19,283		17,466			Total Government Business	23,758		19,283
IngenioRx	IngenioRx						IngenioRx
Pharmacy products and services	Pharmacy products and services	5,862		5,197			Pharmacy products and services	6,683		5,862

Total IngenioRx		5,862		5,197

Other	Other						Other
Integrated health services	Integrated health services	2,249		949			Integrated health services	2,947		2,249
Other	Other	121		78			Other	274		121
Total Other Business	Total Other Business	2,370		1,027			Total Other Business	3,221		2,370
Eliminations	Eliminations						Eliminations
Eliminations	Eliminations	(4,908)		(3,603)			Eliminations	(6,045)		(4,908)
Total product revenues	Total product revenues	$	32,098	$	29,448		Total product revenues	$	37,886	$	32,098

The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed. Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.

-34-

A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:

Three Months Ended
March 31
2021 2020
Reportable segments’ operating revenue $ 32,098 $ 29,448
Net investment income 291 254
Net realized losses on financial instruments (4) (81)
Total revenues $ 32,385 $ 29,621

~~-35-~~


	Three Months Ended March 31
	2022		2021
Reportable segments’ operating revenue	$	37,886	$	32,098
Net investment income	360		291
Net losses on financial instruments	(151)		(4)
Total revenues	$	38,095	$	32,385

A reconciliation of ~~reportable segments’ operating gain to~~ income before income tax expense to reportable segments’ operating gain included in our consolidated statements of income for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:


		Three Months Ended March 31				Three Months Ended March 31
		2021		2020				2022		2021
Reportable segments’ operating gain		$	2,161	$	2,194
Income before income tax expense							Income before income tax expense	$	2,326	$	2,176
Net investment income	Net investment income	291		254			Net investment income	(360)		(291)
Net realized losses on financial instruments		(4)		(81)
Net losses on financial instruments							Net losses on financial instruments	151		4
Interest expense	Interest expense	(192)		(194)			Interest expense	201		192
Amortization of other intangible assets	Amortization of other intangible assets	(80)		(83)			Amortization of other intangible assets	129		80
Loss on extinguishment of debt		0		(1)
Income before income tax expense		$	2,176	$	2,089

Reportable segments’ operating gain							Reportable segments’ operating gain	$	2,447	$	2,161

16. Leases

We lease office space and certain computer and related equipment using ~~noncancelable~~noncancellable operating leases. Our leases have remaining lease terms of 1 year to 1312 years.

The information related to our leases is as follows:


		Balance Sheet Location	March 31, 2021		December 31, 2020			Balance Sheet Location	March 31, 2022		December 31, 2021
Operating Leases	Operating Leases						Operating Leases
Right-of-use assets	Right-of-use assets	Other noncurrent assets	$	628	$	646	Right-of-use assets	Other noncurrent assets	$	599	$	628
Lease liabilities, current	Lease liabilities, current	Other current liabilities	116		110		Lease liabilities, current	Other current liabilities	128		133
Lease liabilities, noncurrent	Lease liabilities, noncurrent	Other noncurrent liabilities	801		847		Lease liabilities, noncurrent	Other noncurrent liabilities	807		864

Three Months Ended
March 31
2021 2020
Lease Expense
Operating lease expense $ 29 $ 47
Short-term lease expense 12 13
Sublease income (1) (3)
Total lease expense $ 40 $ 57
Other information
Operating cash paid for amounts included in the measurement of lease liabilities, operating leases $ 52 $ 44
Right-of-use assets obtained in exchange for new lease liabilities, operating leases $ 14 $ 323


	Three Months Ended March 31
	2022		2021
Lease Expense
Operating lease expense	$	28	$	29
Short-term lease expense	12		12
Sublease income	(1)		(1)
Total lease expense	$	39	$	40

Other information
Operating cash paid for amounts included in the measurement of lease liabilities, operating leases	$	53	$	52
Right-of-use assets obtained in exchange for new lease liabilities, operating leases	$	—	$	14

~~-36-~~-35-

As of March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, the weighted average remaining lease term of our operating leases was 7 ~~years.~~years for each period. The lease liabilities reflect a weighted average discount rate of ~~3.07%~~2.68% at March 31, ~~2021~~2022 and ~~3.21%~~2.69% at December 31, ~~2020.~~2021.

Future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:


2021 (excluding the three months ended March 31, 2021)		$	151
2022		188
2022 (excluding the three months ended March 31, 2022)				2022 (excluding the three months ended March 31, 2022)	$	157
2023	2023	163		2023	194
2024	2024	134		2024	165
2025	2025	94		2025	127
2026				2026	90
Thereafter	Thereafter	243		Thereafter	307
Total future minimum payments	Total future minimum payments	973		Total future minimum payments	1,040
Less imputed interest	Less imputed interest	(56)		Less imputed interest	(105)
Total lease liabilities	Total lease liabilities	$	917	Total lease liabilities	$	935

As of March 31, ~~2021,~~2022, we have additional operating leases for building spaces that have not yet commenced, and some building spaces are being constructed by the lessors and their agents. These leases have terms of up to 1210 years and are expected to commence on various dates during ~~2021~~2022 when the construction is complete and we take possession of the buildings. The undiscounted lease payments for these leases, which are not included in the tables above, aggregate ~~$133.~~

to $41.

~~-37-~~-36-

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(In Millions, Except Per Share Data or as Otherwise Stated Herein)

This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the accompanying consolidated financial statements and notes, our consolidated financial statements and notes as of and for the year ended December 31, ~~2020~~2021 and the MD&A included in our ~~2020~~2021 Annual Report on Form 10-K. References to the terms “we,” “our,” “us,” or “Anthem” used throughout this MD&A refer to Anthem, Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia and Puerto Rico, unless the context otherwise requires.

Results of operations, cost of care trends, investment yields and other measures for the three months ended March 31, ~~2021~~2022 are not necessarily indicative of the results and trends that may be expected for the full year ending December 31, ~~2021,~~2022, or any other period.

Overview

We are one of the largest health benefits companies in the United States in terms of medical membership, serving nearly 4447 million medical members through our affiliated health plans as of March 31, ~~2021.~~2022. We are an independent licensee of the Blue Cross and Blue Shield Association (“BCBSA”), an association of independent health benefit plans. We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield (“BCBS”) licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. ~~We also~~In addition, we conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous states ~~across the country~~ as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, MMM, Optimum HealthCare, Simply Healthcare, and/or UniCare. ~~Pharmacy~~We offer pharmacy benefits management (“PBM”) services ~~are offered~~ through our IngenioRx, Inc. (“IngenioRx”) subsidiary. We are licensed to conduct insurance operations in all 50 states, ~~and~~ the District of Columbia and Puerto Rico through our subsidiaries.

For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our ~~2020~~2021 Annual Report on Form 10-K. Additional information on our segments can be found in this MD&A and in Note 15, “Segment Information” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

COVID-19

~~In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus (“COVID-19”) a global health pandemic.~~ The ~~virus and mitigation efforts have continued~~COVID-19 pandemic continues to impact the global economy, cause market instability ~~increase unemployment~~and uncertainty in the labor market and put pressure on the healthcare ~~system. The COVID-19 pandemic~~system, and it has impacted, and will likely continue to impact, our membership, ~~our~~ benefit expense and ~~member~~members behavior, including how members access healthcare services. ~~Our~~We continue to assist our customers, providers, members and communities in addressing the effects of the COVID-19 pandemic, including by providing expanded benefit coverage for COVID-19 diagnostic tests and vaccine administration and taking steps to increase vaccinations by enabling, educating, and encouraging vaccine acceptance among our members as well as in the communities in which we operate.

COVID-19 care, testing and vaccine administration, and the impact of new COVID-19 variants, have resulted in increased medical costs for us in the first quarter of 2022. In the first quarter of 2022, our Medicaid membership ~~grew since the pandemic~~continued to grow as a result of the temporary suspension of eligibility recertification ~~efforts~~ in response to the COVID-19 pandemic, which we expect will remain suspended at least ~~through~~until the ~~end of 2021. During the first~~third quarter of ~~2021,~~2022. Once eligibility recertification resumes, which may not occur until 2023 in certain states, we expect a decline in our ~~non-COVID-19 healthcare utilization experience remained~~Medicaid membership. At the same time, we expect growth in our Commercial risk-based and fee-based plans, including through Individual on-exchange products through state- or federally-facilitated marketplaces (the “Public Exchange”), as members exiting Medicaid in our fourteen Commercial states seek coverage elsewhere. See “Business Trends - Medical Cost Trends” below pre-COVID-19 levels, partially offsetting our COVID-19 related healthcare utilization, which remained elevated. Our expenses associated with COVID-19, including testing, treatment and vaccine administration exceeded the benefit we experienced during the quarter from the lower volume of healthcare claims attributable to decreased utilization of non-COVID-19 healthcare services.

~~We provided enhanced access and coverage~~ for ~~our members, made changes to select membership benefits and business operations and modified tools and policies to assist consumers and care providers at the height~~a discussion of the impact of COVID-19 ~~pandemic. We continued to waive cost-sharing to~~on our members related to COVID-19 diagnostic tests, treatment and vaccine administration through the first quarter of 2021. Although the COVID-19 pandemic has impacted and will likely continue to impact our membership and benefit expense, and continued COVID-19 care, testing and vaccine administration, and thehealthcare costs.

~~-38-~~-37-

possible risk of new COVID-19 variants are expected to result in increased future medical costs, we have proactively taken actions to minimize these effects, and the pandemic has not had a material adverse effect on our reported results through March 31, 2021. However, this may change in the future as theThe COVID-19 pandemic continues to evolve and the full extent of its impact ~~(including new variants of the virus, which may be more contagious, more severe or less responsive to treatment or vaccines)~~ will depend on future developments, which are highly uncertain and cannot be predicted at this time. We will continue to monitor the COVID-19 pandemic as well as resulting legislative and regulatory changes ~~that may impact~~to manage our response and assess and mitigate potential adverse impacts to our business. For additional discussion regarding our risks related to the COVID-19 pandemic and our other risk factors, see Part I, Item ~~1, “Business–COVID-19”, Part I, Item~~ 1A, “Risk Factors” ~~and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations–COVID-19”~~ included in our ~~2020~~2021 Annual Report on Form 10-K.

Business Trends

~~The Patient Protection and Affordable Care Act and~~We made the ~~Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”) has changed and may continue~~decision to make broad-based changes to the U.S. healthcare system. We expect the ACA will continue to impact our business model and strategy. Also, the legal challenges regarding the ACA, including a federal district court decision invalidating the ACA, which was argued before the U.S. Supreme Court in November 2020 and has been stayed pending the U.S. Supreme Court’s decision, could significantly disrupt our business. In 2020, we modestly ~~expanded~~expand our participation in the ~~Individual ACA-compliant market~~“Public Exchange” for 2022 after also expanding in 2021. As a result, for 2022 we are offering Public Exchange products in 122 of the 143 rating regions in which we operate, in comparison to 103 of 143 rating regions in 2021. Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of confidence that these markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment and underlying market characteristics. ~~We currently offer Individual ACA-compliant products in 103 of~~Changes to our business environment are likely to continue as elected officials at the ~~143 rating regions in which we operate.~~national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and fees. In addition, the continuing growth in our government-sponsored business exposes us to increased regulatory oversight.

~~Beginning in the second quarter of 2019, we began using~~Our IngenioRx ~~to market~~subsidiary markets and ~~offer~~offers PBM services to our affiliated health plan customers throughout the country, as well as to customers outside of the health plans we own. Our comprehensive PBM services portfolio includes ~~services~~features such as formulary management, pharmacy networks, a prescription drug database, member services and mail order capabilities. IngenioRx delegates certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account management and retail network strategy.

Pricing Trends: We strive to price our ~~healthcare~~health benefit products consistent with anticipated underlying medical cost trends. We continue to closely monitor the COVID-19 pandemic (including new COVID-19 variants, which may be more contagious or severe, or less responsive to treatment or vaccines) and the impacts it may have on our pricing, such as surges in COVID-19 related hospitalizations, infection rates, the cost of COVID-19 vaccines, testing and treatment and the return of non-COVID-19 healthcare ~~utilization.~~utilization to our estimate of normal levels, based on historical utilization patterns. We frequently make adjustments to respond to legislative and regulatory changes as well as pricing and other actions taken by existing competitors and new market entrants. Product pricing in our Commercial & Specialty Business segment, including our Individual and ~~Small Group~~small group lines of business, remains competitive. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon annual funding from the federal government and/or applicable state governments. The ACA imposed an annual Health Insurance Provider Fee (“HIP Fee”) on health insurers that write certain types of health insurance on U.S. risks. We priced our affected products to cover the impact of the HIP Fee, when applicable. The HIP Fee has been permanently repealed beginning in 2021.

Medical Cost Trends: Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of these services. We work to mitigate these trends through various medical management programs such as ~~utilization management,~~care and condition management, program integrity and specialty pharmacy management and utilization management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics of our members, epidemics, pandemics, advances in medical technology, new ~~high cost~~high-cost prescription drugs, and healthcare provider or member fraud.

~~The~~At its onset, the COVID-19 pandemic ~~has~~ caused a decrease in utilization of non-COVID-19 health services, which decreased our claim costs in 2020. ~~During~~As the pandemic continued through 2021, our non-COVID-19 healthcare utilization experience gradually increased and largely normalized. Our COVID-19 related healthcare expenses increased during 2021 as new variants (Delta and Omicron) emerged and vaccinations and boosters became available.

The Omicron surge quickly declined during the first quarter of ~~2021, non-COVID~~2022, with COVID-19 inpatient authorizations, provider-based tests, visits and vaccinations all decreasing to lower levels by the end of the first quarter of 2022; concurrently, non-COVID-19 healthcare utilization ~~experience remained below our pre-COVID-19~~recovered from lower levels ~~partially offsetting our~~earlier in the quarter. In 2022, we anticipate additional claim costs for new pharmaceutical treatments for COVID-19 ~~related healthcare utilization, which remained elevated.~~and compliance with governmental regulations on COVID-19 testing reimbursement. We expect claims costs related to COVID-19 testing, treatment and hospitalizations will continue throughout 2022 even during periods with lower COVID-19 infection and confirmed case activity. The ongoing cost and volume of

~~-39-~~-38-

~~utilization of non-COVID-19 healthcare~~covered services to rebound and for claim costs to normalize in 2021. Further increases and pent-up demand in the utilization of such services may increase our claim costs in the future and affect our medical cost trends. Our expenses in 2020 and the first quarter of 2021 included additional costs to cover COVID-19 related testing, treatment and vaccine administration. During the first quarter of 2021, through various dates, we continued to provide expanded coverage for certain members for treatment related to the COVID-19 pandemic may have a ~~COVID-19 diagnosis. Governmental action has required us to provide varying coverage for COVID-19 testing and vaccine administration to~~material adverse effect on our ~~members. Continued COVID-19 care, testing and vaccine administration, and the possible risk of new COVID-19 variants, are expected to result in increased~~ future ~~medical~~claim costs. We continue to closely monitor the COVID-19 pandemic and its impacts on our business, financial condition, results of operations and medical cost trends.

For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our ~~2020~~2021 Annual Report on Form 10-K.

Regulatory Trends and Uncertainties

Federal and state governments have enacted, and may continue to enact, legislation and regulations in response to the COVID-19 pandemic that have had, and we expect will continue to have, a significant impact on ~~healthcare~~health benefits, consumer eligibility for public programs and our cash flows for all ~~of our~~ lines of ~~business.~~business, and which have introduced increased uncertainty around our cost structure. These actions, which are or have been in effect for various durations, provide, among other things:

•mandates to waive cost-sharing onfor COVID-19 testing ~~treatment,~~(including over-the-counter testing in accordance with state and federal requirements), vaccines and related services;

•reforms, including waiving Medicare originating site restrictions for qualified providers ~~providing~~of telehealth services;

•financial support to healthcare providers, including expansion of the Medicare accelerated payment program to all providers receiving Medicare payments;

•mandated expansion of premium payment terms, including the time period for which claims can be denied for lack of payment; and

•mandates related to prior authorizations and payment levels to providers, additional consumer enrollment windows and an increased ability to provide telehealth services.

Beginning in July 2022, the health plan price transparency regulations issued in October 2020 by the U.S. Departments of Health and Human Services, Labor and Treasury (the “Health Plan Transparency Rule”) will require us to disclose, on a monthly basis, detailed pricing information regarding negotiated rates for all covered items and services between the plan or issuer and in-network providers and historical payments to, and billed charges from, out-of-network providers. Additionally, beginning in 2023, we will be required to make available to members personalized out-of-pocket cost information and the underlying negotiated rates for 500 covered healthcare items and services, including prescription drugs. In 2024, this requirement will expand to all items and services.

The Consolidated Appropriations Act of 2021, which was enacted in December 2020 (the “Appropriations Act”) ~~contains a number of provisions that~~, has impacted and in the future may have a material effect upon our business, including procedures and coverage requirements related to surprise medical bills and new mandates for continuity of care for certain patients, price comparison tools, disclosure of broker compensation, mental health parity reporting, and reporting on pharmacy benefits and drug costs. The ~~various health plan-related~~ requirements of the Appropriations Act ~~will go into effect on January 1, 2022,~~applicable to us have varying effective dates, some of which were effective in December 2021 and ~~our first report on pharmacy benefits and drug costs is due December 27, 2021.~~others that have been extended since the enactment of the Appropriations Act.

The ~~ACA presented us with new growth opportunities, but also~~American Rescue Plan Act of 2021, (the “Rescue Plan”), which was enacted in March 2021, contains several health-related provisions that have impacted our business, including expansion of premium tax credits for our Public Exchange business and full subsidization of the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) continuation coverage for those who were involuntarily terminated or had their work hours reduced. The Rescue Plan’s premium tax credit provisions became effective in January 2021, while the COBRA premium subsidization was effective from April 2021 through September 2021.

Since its enactment in 2010, the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended (collectively, the “ACA”), has introduced new risks, regulatory challenges and uncertainties, has impacted our business model and strategy and has required changes in the way our products are designed, underwritten, priced, distributed and administered. ~~Changes~~The ACA has evolved and various challenges since its enactment have introduced increased uncertainty to our business environment are likely to continue as elected officials at the national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and regulations, including changes to taxes and fees.business. In ~~addition, the legal challenges regarding the ACA continue to contribute to this uncertainty, including a federal district court decision invalidating the ACA in its entirety, which was argued before~~June 2021, the U.S. Supreme Court issued its opinion and dismissed the last legal challenge to the constitutionality of the ACA, leaving the law intact. We expect the ACA will continue to significantly impact our business and results of operations, including pricing, minimum medical loss ratios and the geographies in ~~November 2020~~which our products are available, and ~~has been stayed pending~~as a result of future modifications of, and guidance by federal regulatory

-39-

agencies related to, the ~~U.S. Supreme Court’s decision.~~ACA and our businesses more broadly. We will continue to evaluate the impact of the ACA as any further developments ~~or judicial rulings~~ occur.

The annual HIP Fee, which has been permanently eliminated effective in 2021, was allocated to health insurers based on the ratio of the amount of an insurer’s net premium revenues written during the preceding calendar year to the amount of health insurance premium for all U.S. health risk for those certain lines of business written during the preceding calendar year. The HIP Fee was non-deductible for federal income tax purposes. Our affected products were priced to cover the increased selling, general and administrative and income tax expenses associated with the HIP Fee when applicable. The total amount due from allocations to all health insurers was $15,523 for 2020. For the three months ended March 31, 2020, we recognized $417 as selling, general and administrative expense related to the HIP Fee.

~~-40-~~

For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business – Regulation”, Part I, Item 1A, “Risk Factors”, and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our ~~2020~~2021 Annual Report on Form 10-K.

Other Significant Items

Business and Operational Matters

On March ~~24,~~10, 2022, we announced our intent to change our name to better reflect our business and our journey from a traditional health benefits organization to a lifetime, trusted health partner. At our annual meeting of shareholders on May 18, 2022, our shareholders will vote on a proposed amendment to our amended and restated articles of incorporation to change our name to Elevance Health, Inc. Shareholders of record on March 17, 2022 are entitled to vote. If approved by our shareholders, we expect the name change to occur in the second quarter of 2022.

On November 10, 2021, we announced our entrance into an agreement with ~~WindRose Health Investors~~Personal Touch Holding Corporation to acquire ~~myNEXUS, Inc.~~Integra Managed Care (“~~myNEXUS”~~Integra”). ~~myNEXUS~~Integra is a ~~comprehensive home-based nursing management company for payors~~managed long-term care plan that serves New York state Medicaid members, enabling adults with long-term care needs and ~~delivers integrated clinical support services for Medicare Advantage members across twenty states. This acquisition aligns with our strategy~~disabilities to ~~manage integrated, whole person multi-site care~~live safely and ~~support, by providing national, large-scale expertise to manage nursing services~~independently in ~~the home and facilitate transitions of care.~~their own homes. The acquisition is expected to close by the end of the second quarter of ~~2021~~2022 and is subject to standard closing conditions and customary approvals.

On ~~February 2,~~June 29, 2021, we ~~announced~~completed our ~~entrance into an agreement with InnovaCare Health, L.P. to acquire its Puerto Rico-based subsidiaries, including~~acquisition of MMM Holdings, LLC (“MMM”), and its Medicare Advantage plan, Medicaid plan and other affiliated ~~companies.~~companies from InnovaCare Health, L.P. MMM is ana Puerto Rico-based integrated healthcare organization and seeks to provide its Medicare Advantage and Medicaid members with a whole health experience through its network of specialized clinics and wholly owned independent physician associations. This acquisition aligns with our vision to be an innovative, valuable and inclusive healthcare partner by providing care management programs that improve the lives of the people we serve. ~~The~~

On April 28, 2021, we completed our acquisition of myNEXUS, Inc. (“myNEXUS”) from WindRose Health Investors. myNEXUS is ~~expected~~a comprehensive home-based nursing management company for payors and, at the time of acquisition, delivered integrated clinical support services for Medicare Advantage members across twenty states. This acquisition aligns with our strategy to ~~close~~manage integrated, whole person multi-site care and support by providing national, large-scale expertise to manage nursing services in the ~~end~~home and facilitate transitions of care.

For additional information, see Note 3, “Business Acquisitions,” of the ~~second quarter~~Notes to Consolidated Financial Statements included in Part I, Item 1 of ~~2021 and is subject to standard closing conditions and customary approvals.~~this Form 10-Q.

In 2020, we introduced enterprise-wide initiatives to optimize our business and as a result, recorded a charge of $653 in selling, general and administrative ~~expenses for the year ended December 31, 2020.~~expenses. We believe these initiatives largely represent the next step forward in our progression towards becoming a more agile organization, including process automation and a reduction in our office space footprint. In the fourth quarter of 2021, we identified additional office space reductions and related fixed asset impairments due to the continuing COVID-19 pandemic and recorded a charge of $202 in selling general and administrative expenses. For additional information, see Note 4, “Business Optimization Initiatives” and Note 16, “Leases,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this ~~Form 10-Q.~~

On February 28, 2020, we completed our acquisition of Beacon Health Options, Inc., (“Beacon”), the largest independently held behavioral health organization in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligned with our strategy to diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions. For additional information, see Note 3, “Business Acquisitions,” of the Notes to Consolidated Financial Statements included in Part 1, Item 1 of thisQuarterly Report on Form 10-Q.

Litigation Matters

In the consolidated multi-district proceeding in the United States District Court for the Northern District of Alabama (the “Court”) captioned In re Blue Cross Blue Shield Antitrust Litigation (“BCBSA Litigation”), the BCBSA and Blue Cross and/or Blue Shield licensees, including us (the “Blue plans”) have approved a settlement agreement and release (the “Subscriber Settlement Agreement”) with the plaintiffs representing a putative nationwide class of health plan subscribers. Generally, the lawsuits in the BCBSA Litigation challenge elements of the licensing agreements between the BCBSA and the independently owned and operated Blue plans. The cases were brought by two putative nationwide classes of plaintiffs, health plan

-40-

subscribers and providers, and the Subscriber Settlement Agreement applies only to the putative subscriber class. No settlement agreement has been reached with the provider plaintiffs at this time, and the defendants continue to contest the consolidated cases brought by the provider plaintiffs.

If approved by the Court, the Subscriber Settlement Agreement will require the defendants to make a monetary settlement payment, our portion of which is estimated to be $594, and will ~~contain~~include certain terms imposing non-monetary ~~terms.~~obligations on the defendants. As of March 31, ~~2021,~~2022, the liability balance accrued for our estimated remaining payment obligation was $507, net of payments made. All terms of the Subscriber Settlement Agreement are subject to ~~final~~ approval by the Court before they become effective. For additional information regarding ~~this lawsuit,~~the BCBSA Litigation, see Note 11, “Commitments and Contingencies – Litigation and Regulatory Proceedings – Blue Cross Blue Shield Antitrust Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this ~~Form 10-Q.~~

~~-41-~~

In August 2020, the Delaware Court of Chancery ruled that neither we nor Cigna Corporation (“Cigna”) could collect damages in connection with the now terminated Agreement and Plan of Merger between us and Cigna. Cigna filed a notice of appeal in November 2020 challenging the trial court’s opinion that Anthem did not owe Cigna a termination fee. Cigna filed its appellate brief in December 2020, and we filed a response in January 2021. Oral argument before the Delaware Supreme Court was held in April 2021. The matter was taken under advisement. For additional information, see Note 11, “Commitments and Contingencies – ~~Litigation and Regulatory Proceedings – Cigna Corporation Merger Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.~~

In January 2019, we exercised our contractual right to terminate our PBM agreement with Express Scripts, Inc. (the “ESI PBM Agreement”) and we completed the transition of our members from Express Scripts to IngenioRx by January 1, 2020. Notwithstanding our termination of the ESI PBM Agreement, the litigation between us and Express Scripts regarding the ESI PBM Agreement continues. For additional information regarding this lawsuit, see Note 11, “Commitments and Contingencies – ~~Litigation and Regulatory Proceedings – Express Scripts, Inc. Pharmacy Benefit Management Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this~~Quarterly Report on Form 10-Q.

Selected Operating Performance

For the twelve months ended March 31, ~~2021,~~2022, total medical membership increased ~~1.4,~~by 3.3 million, or ~~3.3%~~7.5%. ~~Our medical membership grew primarily due to membership increases in our Government Business segment, partially offset by declines in our Commercial & Specialty Business segment.~~ The increase ~~in our Government Business membership~~ was driven primarily ~~driven~~ by organic growth in our Medicaid business due to the continued temporary suspension of eligibility recertification during the COVID-19 pandemic, ~~which we expect will remain suspended at least~~the acquisitions of MMM in the second quarter of 2021 and Ohio Medicaid members in the first quarter of 2022 through the ~~end~~purchase of a Medicaid contract and the launch of our HealthyBlue managed care alliance in North Carolina in the third quarter of 2021. ~~The increase in our Government Business~~Our Medicare Advantage membership ~~was further~~also increased due to ~~higher sales in our Medicare Advantage business exceeding lapses. The decrease~~organic growth. Increases in our Commercial & Specialty Business ~~membership was~~segment were driven primarily ~~driven~~ by new sales exceeding lapses in both our Group fee-based ~~business, which experienced higher in-group change as a result of increased unemployment caused by the COVID-19 pandemic, partially offset by sales in~~and our ~~Individual business exceeding lapses.~~Group risk-based membership.

Operating revenue for the three months ended March 31, ~~2021~~2022 was ~~$32,098,~~$37,886, an increase of ~~$2,650,~~$5,788, or ~~9.0%~~18.0%, from the three months ended March 31, ~~2020. The~~2021. This increase in operating revenue ~~for the three months ended March 31, 2021 compared to 2020~~ was primarily driven by higher premium revenue due mainly to organic membership growth in our ~~Government Business segment~~Medicaid business resulting primarily from the continued temporary suspension of eligibility recertification during the COVID-19 pandemic. Other contributors to the operating revenue increase were the acquisition of MMM in the second quarter of 2021, the acquisition of Ohio Medicaid members in the first quarter of 2022 through the purchase of a Medicaid contract and ~~higher~~the retroactive reinstatement of a Medicaid directed payment program. Membership increases and rate increases designed to cover medical cost trends in our Medicare Advantage and Commercial risk-based businesses also provided additional premium revenue. Product revenue increased due to growth in integrated pharmacy ~~product revenue~~members in our IngenioRx ~~segment.~~segment which also contributed to the overall operating revenue increase.

Net income for the three months ended March 31, ~~2021~~2022 was ~~$1,667,~~$1,795, an increase of ~~$144,~~$128, or ~~9.5%~~7.7%, from the three months ended March 31, ~~2020. The~~2021. This increase in net income was primarily due to a net operating gain increase from our business units and increased net investment income, partially offset by increased losses on financial instruments, increased interest expense, increased amortization of intangibles and increased income tax expense due to higher income before income tax expense.

Our fully-diluted shareholders’ earnings per share (“EPS”) was $7.39 for the three months ended March 31, 2021 was primarily due to lower net realized losses on financial instruments, improved operating gain in our Government Business and IngenioRx segments, lower income tax expense, and improved investment income, partially offset by2022, which represented a ~~decline in operating gain in our Commercial & Specialty Business segment.~~

~~Our fully-diluted earnings per share (“EPS”) was~~10.1% increase from EPS of $6.71 for the three months ended March 31, ~~2021, which represented a 13.0% increase from EPS of $5.94~~2021. Our diluted shares for the three months ended March 31, ~~2020. The increase in EPS for~~2022 were 244.4, a decrease of 3.8, or 1.5%, compared to the three months ended March 31, ~~2021 compared to 2020~~2021. The increase in EPS resulted primarily from the increase in net income, as well as afrom the lower ~~number of diluted~~ shares outstanding ~~in 2021.~~during the three months ended March 31, 2022.

Operating cash flow for the three months ended March 31, 2022 and 2021 was $2,541 and ~~2020 was~~ $2,505, ~~and $2,515,~~ respectively. ~~Operating~~The minor increase in operating cash flow was ~~driven by changes in working capital, the impact of membership growth in our Government Business segment and~~due to higher net income in ~~2021~~2022, partially offset by the impact of ~~the repeal of the HIP Fee in 2021.~~working capital changes year over year.

~~-42-~~-41-

Membership

In 2021, we have updated our medical membership reporting to better align with how we view our business. Our medical membership now includes the following customer types: Individual, Group risk-based, Group fee-based, BlueCard®, Medicare, Medicaid and our Federal Employees Health Benefits (“FEHB”) Program. BCBS-branded business generally refers to members in our service areas licensed by the BCBSA. Non-BCBS-branded business refers to members in our non-BCBS-branded Amerigroup, Freedom Health, HealthSun, Optimum HealthCare and Simply Healthcare plans, as well as HealthLink and UniCare members. In addition to the above medical membership, we also serve customers who purchase one or more of our other products or services that are often ancillary to our health business.

•Individual consists of individual customers under age 65 and their covered dependents. Individual policies are generally sold through independent agents and brokers, retail partnerships, our in-house sales force or via the exchanges. Individual business is sold on a risked-based basis. We offer on-exchange products through public exchanges and off-exchange products. Federal premium subsidies are available only for certain public exchange Individual products. Unsubsidized Individual customers are generally more sensitive to product pricing and, to a lesser extent, the configuration of the network and the efficiency of administration. Customer turnover is generally higher with Individual as compared to Group risk-based business.

•Group risk-based consists of employer customers who purchase products on a full-risk basis, which are products for which we charge a premium and indemnify our policyholders against costs for health benefits. Group risk-based accounts include Local Group customers and National Accounts. Local Group consists of those employer customers with less than 5% of eligible employees located outside of the headquarter state, as well as customers with more than 5% of eligible employees located outside of the headquarter state with up to 5,000 eligible employees. In addition, Local Group includes Student Health members. National Accounts generally consist of multi-state employer groups primarily headquartered in an Anthem service area with at least 5% of the eligible employees located outside of the headquarter state and with more than 5,000 eligible employees. Some exceptions are allowed based on broker and consultant relationships. Group risk-based accounts are generally sold through brokers or consultants who work with industry specialists from our in-house sales force and are offered both on and off the public exchanges.

•Group fee-based customers represent employer groups, Local Group, including UniCare members, and National Accounts, who purchase fee-based products and elect to retain most or all of the financial risk associated with their employees’ healthcare costs. Some fee-based customers choose to purchase stop loss coverage to limit their retained risk. Group fee-based accounts are generally sold through independent brokers or consultants retained by the customer working with our in-house sales force.

•~~BlueCard~~® ~~host customers represent enrollees of Blue Cross and/or Blue Shield plans not owned by Anthem who receive healthcare services in our BCBSA licensed markets. BlueCard~~® ~~membership consists of estimated host members using the national BlueCard~~® program. Host members are generally members who reside in or travel to a state in which an Anthem subsidiary is the Blue Cross and/or Blue Shield licensee and who are covered under an employer-sponsored health plan issued by a non-Anthem controlled BCBSA licensee (the “home plan”). We perform certain functions, including claims pricing and administration, for BlueCard® ~~members, for which we receive administrative fees from the BlueCard~~® members’ home Blue plans. Other administrative functions, including maintenance of enrollment information and customer service, are performed by the home Blue plan. Host members are computed using, among other things, the average number of BlueCard® ~~claims received per month.~~

•Medicare customers are Medicare-eligible individual members age 65 and over who have enrolled in Medicare Supplement plans; Medicare Advantage, including Special Needs Plans (“SNPs”), also known as Medicare Advantage SNPs; Medicare Part D; and dual-eligible programs through Medicare-Medicaid Plans (“MMPs”). Medicare Supplement plans typically pay the difference between healthcare costs incurred by a beneficiary and amounts paid by Medicare. Medicare Advantage plans provide Medicare beneficiaries with a managed care alternative to traditional Medicare and often include a Medicare Part D benefit. In addition, our Medicare Advantage SNPs provide tailored benefits to special needs individuals who are institutionalized or have severe or disabling chronic conditions and to dual-eligible customers, who are low-income seniors and persons under age 65 with disabilities. Medicare Advantage SNPs are coordinated care plans specifically designed to provide targeted care, covering all the healthcare services considered medically necessary for members and often providing professional care coordination services, with personal guidance and programs that help members maintain their health. Medicare Advantage membership also includes Medicare Advantage members in our Group Retiree Solutions business who

~~-43-~~

are retired members of Commercial accounts or retired members of groups who are not affiliated with our Commercial accounts who have selected a Medicare Advantage product through us. Medicare Part D offers a prescription drug plan to Medicare and MMP beneficiaries. MMP, which was established as a result of the passage of the ACA, is a demonstration program focused on serving members who are dually eligible for Medicaid and Medicare. Medicare Supplement and Medicare Advantage products are marketed in the same manner, primarily through independent agents and brokers.

•Medicaid membership represents eligible members who receive healthcare benefits through publicly funded healthcare programs, including Medicaid, ACA-related Medicaid expansion programs, Temporary Assistance for Needy Families, programs for seniors and people with disabilities, Children’s Health Insurance Programs, and specialty programs such as those focused on long-term services and support, HIV/AIDS, foster care, behavioral health and/or substance abuse disorders, and intellectual disabilities or developmental disabilities, among others.

•FEHB members consist of United States government employees and their dependents within our geographic markets through our participation in the national contract between the BCBSA and the U.S. Office of Personnel Management.

The following table presents our medical membership by reportable segment and customer type as of March 31, ~~2021~~2022 and ~~2020.~~2021. Also included below is other membership by product. The medical membership and other membership data presented are unaudited and in certain instances include estimates of the number of members represented by each contract at the end of the period. For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 2021 Annual Report on Form 10-K.


		March 31						March 31
(In thousands)	(In thousands)	2021	2020	Change	% Change		(In thousands)	2022	2021	Change	% Change
Medical Membership	Medical Membership						Medical Membership
Commercial & Specialty Business:	Commercial & Specialty Business:						Commercial & Specialty Business:
Individual	Individual	731	717	14	2.0	%	Individual	818	731	87	11.9	%
Group Risk-Based	Group Risk-Based	3,837	3,841	(4)	(0.1)	%	Group Risk-Based	4,028	3,837	191	5.0	%
Commercial Risk-Based	Commercial Risk-Based	4,568	4,558	10	0.2	%	Commercial Risk-Based	4,846	4,568	278	6.1	%
BlueCard®		6,166	6,197	(31)	(0.5)	%
BlueCard®							BlueCard®	6,370	6,166	204	3.3	%
Group Fee-Based	Group Fee-Based	19,515	19,905	(390)	(2.0)	%	Group Fee-Based	20,148	19,515	633	3.2	%
Commercial Fee-Based	Commercial Fee-Based	25,681	26,102	(421)	(1.6)	%	Commercial Fee-Based	26,518	25,681	837	3.3	%
Total Commercial & Specialty Business	Total Commercial & Specialty Business	30,249	30,660	(411)	(1.3)	%	Total Commercial & Specialty Business	31,364	30,249	1,115	3.7	%
Government Business:	Government Business:						Government Business:
Medicare Advantage	Medicare Advantage	1,538	1,341	197	14.7	%	Medicare Advantage	1,921	1,538	383	24.9	%
Medicare Supplement	Medicare Supplement	930	914	16	1.8	%	Medicare Supplement	939	930	9	1.0	%
Total Medicare	Total Medicare	2,468	2,255	213	9.4	%	Total Medicare	2,860	2,468	392	15.9	%
Medicaid	Medicaid	9,172	7,615	1,557	20.4	%	Medicaid	10,919	9,172	1,747	19.0	%
Federal Employees Health Benefits	Federal Employees Health Benefits	1,632	1,614	18	1.1	%	Federal Employees Health Benefits	1,632	1,632	—	—	%
Total Government Business	Total Government Business	13,272	11,484	1,788	15.6	%	Total Government Business	15,411	13,272	2,139	16.1	%
Total Medical Membership	Total Medical Membership	43,521	42,144	1,377	3.3	%	Total Medical Membership	46,775	43,521	3,254	7.5	%
Other Membership	Other Membership						Other Membership
Life and Disability Members	Life and Disability Members	4,766	5,158	(392)	(7.6)	%	Life and Disability Members	4,679	4,766	(87)	(1.8)	%
Dental Members	Dental Members	6,599	6,476	123	1.9	%	Dental Members	6,649	6,599	50	0.8	%
Dental Administration Members	Dental Administration Members	1,488	1,311	177	13.5	%	Dental Administration Members	1,588	1,488	100	6.7	%
Vision Members	Vision Members	7,798	7,510	288	3.8	%	Vision Members	9,211	7,798	1,413	18.1	%
Medicare Part D Standalone Members	Medicare Part D Standalone Members	450	383	67	17.5	%	Medicare Part D Standalone Members	279	450	(171)	(38.0)	%

Medical Membership

Total medical membership increased ~~primarily due to growth~~in both our Commercial & Specialty Business and Government Business segments. The largest increase was in our Government Business ~~which was driven by~~segment, primarily due to organic ~~growth in our~~ Medicaid membership ~~as a result of~~growth resulting from the continued temporary suspension of eligibility recertification during the

~~-44-~~

COVID-19 ~~pandemic. The increase~~pandemic, the acquisitions of MMM in the second quarter of 2021 and Ohio Medicaid members through the purchase of a Medicaid contract in the first quarter of 2022, as well as the launch of our ~~Government Business~~HealthyBlue managed care alliance in North Carolina in the third quarter of 2021. Our Medicare Advantage membership ~~was further~~also increased due to ~~higher sales in our Medicare Advantage business exceeding the lapses. These increases were partially offset by a decrease~~organic growth. Increases in our Commercial & Specialty Business ~~group~~segment were driven primarily by new sales exceeding lapses in both our Group fee-based and Group risk-based membership. BlueCard membership ~~attributable~~increases and Individual membership increases due to ~~higher in-group change as a result of increased unemployment caused by the COVID-19 pandemic, partially offset by sales~~our Public Exchange expansion in 2022 also contributed to our ~~Individual business exceeding lapses.~~overall membership increases.

Other Membership

Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to our health business. Life and disability membership decreased primarily due to lapses and negative in-group change exceeding membership increases in our Group fee-based business. Dental membership

-42-

increased primarily due to sales exceeding lapses in our Group risk-based accounts and penetration increases in our Federal Employees Health Benefits (“FEHB”) program, partially offset by the loss of a ~~group risk-based account and membership decrease in our group~~significant Group fee-based ~~business. Vision membership increased as a result of growth in our Medicare business.~~account. Dental administration ~~membership increased due to growth in our FEHB program. Dental~~ membership increased primarily due to ~~higher~~increased sales to other BCBS plans associated with the FEHB program. Vision membership increased primarily due to the launch of a new entry level vision product in our ~~Individual and group accounts and~~Group markets, as well as the growth in our ~~FEHB~~Medicare Advantage business. Medicare Part D Standalone membership declined as we discontinued certain legacy products.

Consolidated Results of Operations

Our consolidated summarized results of operations and other financial information for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 are as follows:


								Three Months Ended March 31
		Three Months Ended March 31
		2021			2020				Change		% Change			2022			2021			Change		% Change
Total operating revenue	Total operating revenue	$	32,098		$	29,448			$	2,650	9.0	%	Total operating revenue	$	37,886		$	32,098		$	5,788	18.0	%
Net investment income	Net investment income	291			254				37		14.6	%	Net investment income	360			291			69		23.7	%
Net realized losses on financial instruments		(4)			(81)				77		95.1	%
Net losses on financial instruments													Net losses on financial instruments	(151)			(4)			(147)		NM
Total revenues	Total revenues	32,385			29,621				2,764		9.3	%	Total revenues	38,095			32,385			5,710		17.6	%
Benefit expense	Benefit expense	23,699			21,489				2,210		10.3	%	Benefit expense	28,215			23,699			4,516		19.1	%
Cost of products sold	Cost of products sold	2,313			1,984				329		16.6	%	Cost of products sold	2,883			2,313			570		24.6	%
Selling, general and administrative expense	Selling, general and administrative expense	3,925			3,781				144		3.8	%	Selling, general and administrative expense	4,341			3,925			416		10.6	%
Other expense1	Other expense1	272			278				(6)		(2.2)	%	Other expense1	330			272			58		21.3	%
Total expenses	Total expenses	30,209			27,532				2,677		9.7	%	Total expenses	35,769			30,209			5,560		18.4	%
Income before income tax expense	Income before income tax expense	2,176			2,089				87		4.2	%	Income before income tax expense	2,326			2,176			150		6.9	%
Income tax expense	Income tax expense	509			566				(57)		(10.1)	%	Income tax expense	531			509			22		4.3	%

Net income	Net income	$	1,667		$	1,523			$	144	9.5	%	Net income	$	1,795		$	1,667		$	128	7.7	%
Net income attributable to noncontrolling interests		(2)			—				(2)		NM
Net loss (income) attributable to noncontrolling interests													Net loss (income) attributable to noncontrolling interests	10			(2)			12		NM
Shareholders’ net income	Shareholders’ net income	$	1,665		$	1,523			$	142	9.3	%	Shareholders’ net income	$	1,805		$	1,665		$	140	8.4	%

Average diluted shares outstanding	Average diluted shares outstanding	248.2			256.4				(8.2)		(3.2)	%	Average diluted shares outstanding	244.4			248.2			(3.8)		(1.5)	%

Diluted shareholders’ net income per share	Diluted shareholders’ net income per share	$	6.71		$	5.94			$	0.77	13.0	%	Diluted shareholders’ net income per share	$	7.39		$	6.71		$	0.68	10.1	%
Effective tax rate	Effective tax rate	23.4		%	27.1		%				(370) bp3		Effective tax rate	22.8		%	23.4		%			(60) bp3
Benefit expense ratio2	Benefit expense ratio2	85.6		%	84.2		%				140 bp3		Benefit expense ratio2	86.1		%	85.6		%			50 bp3
Selling, general and administrative expense ratio4	Selling, general and administrative expense ratio4	12.2		%	12.8		%				(60) bp3		Selling, general and administrative expense ratio4	11.5		%	12.2		%			(70) bp3
Income before income tax expense as a percentage of total revenues	Income before income tax expense as a percentage of total revenues	6.7		%	7.1		%				(40) bp3		Income before income tax expense as a percentage of total revenues	6.1		%	6.7		%			(60) bp3
Shareholders' net income as a percentage of total revenues		5.1		%	5.1		%				0 bp3
Shareholders’ net income as a percentage of total revenues													Shareholders’ net income as a percentage of total revenues	4.7		%	5.1		%			(40) bp3

Certain of the following definitions are also applicable to all other results of operations tables in this discussion:

NM Not meaningful.

1 Includes interest expense and amortization of other intangible ~~assets and loss on extinguishment of debt.~~assets.

2 Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the three months ended March 31, 2022 and 2021 were $32,785 and ~~2020 were~~ $27,676, ~~and $25,517,~~ respectively.

3 bp = basis point; one hundred basis points = 1%.

4 Selling, general and administrative expense ratio represents selling, general and administrative expense as a percentage of total operating revenue.

~~-45-~~

Three Months Ended March 31, ~~2021~~2022 Compared to the Three Months Ended March 31, ~~2020~~2021

Total operating revenue increased primarily as a result of higher premium revenue due mainly to organic membership growth in our ~~Government Business segment related~~Medicaid business resulting primarily from the continued temporary suspension of eligibility recertification during the COVID-19 pandemic. Other contributors to ~~our Medicaid and Medicare businesses. The increase in~~the operating revenue ~~was~~increase were the acquisition of MMM in the second quarter of 2021, the acquisition of Ohio Medicaid members in the first quarter of 2022 through the purchase of a Medicaid contract and the retroactive reinstatement of a Medicaid directed payment program. Membership increases and rate increases designed to cover medical cost trends in our Medicare Advantage and Commercial risk-based businesses also ~~the result of~~

-43-

provided additional premium revenue. Product revenue increased due to growth in integrated pharmacy ~~product revenue within~~members in our IngenioRx ~~segment. These increases in~~segment which also contributed to the overall operating revenue ~~were partially offset by the impact of lower premium revenue due to the repeal of the HIP Fee in 2021 and certain retroactive rate adjustments and experience-rated refunds in our Medicaid business.~~increase.

Net investment income increased primarily due to ~~an increase~~increases in net income from ~~other invested assets, partially offset by lower yields on~~our alternative investments and higher income from fixed maturity securities.

Net ~~realized~~ losses on financial instruments ~~decreased~~increased primarily ~~due to an increase in gains from sales~~as a result of ~~our fixed maturity securities, other invested assets and equity securities. In addition, credit~~increased losses on fixed maturity securities ~~declined year-over-year. These improvements~~and fewer gains on equity securities. Losses related to our Russia and Ukraine fixed maturity securities were ~~partially offset by a decline in the fair value~~not material. At March 31, 2022, our remaining holdings of ~~our equity~~Russia and Ukraine fixed maturity securities ~~which is recognized in earnings.~~were not material.

Benefit expense increased primarily due to ~~increased~~healthcare costs ~~resulting from~~associated with organic membership growth in our Medicaid and Medicare businesses, ~~as well as~~the acquisition of MMM in the second quarter of 2021, the acquisition of Ohio Medicaid members in the first quarter of 2022 through the purchase of a Medicaid contract and the retroactive reinstatement of a Medicaid directed payment program. Higher healthcare costs in our Commercial risk-based business also contributed to the increased ~~expense for COVID-19 related costs. These~~ benefit ~~expense increases were partially offset by decreased utilization of non-COVID-19 healthcare services in 2021.~~expense.

Our benefit expense ratio increased primarily due to ~~costs associated with COVID-19, including testing and vaccine administration, and to a lesser extent,~~ the impact of ~~the repeal of the HIP Fee~~continued increases in ~~2021. These increases were partially offset by lower non-COVID-19~~our Government Business segment membership, which has a higher benefit expense ratio than our Commercial & Specialty Business segment membership. Higher healthcare ~~utilization~~costs in ~~2021 and the impact of one less calendar day compared~~our Commercial risk-based businesses also contributed to the ~~first quarter of 2020.~~benefit expense ratio increase.

Cost of products sold reflects the cost of pharmaceuticals dispensed by IngenioRx for our unaffiliated PBM customers. Cost of products sold increased as the corresponding pharmacy product revenues increased.

Selling, general and administrative expense increased primarily due to the increased ~~spend~~costs to support growth in our businesses, higher employee incentive compensation costs and increased premium taxes as a result of the growth in our premiums. These increases were partially offset by the repeal of the HIP Fee in 2021.growth.

Our selling, general and administrative expense ratio decreased primarily due to the ~~repeal of the HIP Fee in 2021 and the~~operating revenue growth in ~~our operating revenue. These decreases were~~2022, partially offset by increased ~~selling, general and administrative expense, as discussed in the preceding paragraph.~~

~~Our effective income tax rate decreased primarily due~~costs to ~~the elimination of the non-tax deductible HIP Fee in 2021.~~support growth.

Our shareholders’ net income as a percentage of total revenues ~~remained level~~decreased in ~~2021~~2022 as compared to ~~2020~~2021 as a result of all factors discussed above.

Reportable Segments Results of Operations

Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted accounting principles (“GAAP”). We also calculate operating gain and operating margin to further aid investors in understanding and analyzing our core operating results and comparing them among periods. We define operating revenue as premium income, product revenue and administrative fees and other revenue. Operating gain is calculated as total operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. It does not include net investment income, net ~~realized losses~~gains (losses) on financial instruments, interest expense, amortization of other intangible assets ~~loss on extinguishment of debt~~ or income taxes, as these items are managed in our corporate shared service environment and are not the responsibility of operating segment management. Operating margin is calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating segment performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This information is not intended to be considered in isolation or as a substitute for income before income tax expense, shareholders’ net income or EPS prepared in accordance with GAAP, and may not be comparable to similarly titled measures reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total revenue included in the consolidated statements of income and

~~-46-~~

a reconciliation of ~~reportable segments’ operating gain to~~ income before income tax expense to reportable segments’ operating gain, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

Results of our operations are described through four reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. For additional information, see Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

-44-

The following table presents a summary of the reportable segment financial information for the three months ended March 31, ~~2021~~2022 and ~~2020:~~2021:


											Three Months Ended March 31
												Three Months Ended March 31
		Three Months Ended March 31												Three Months Ended March 31
		2021			2020			Change		% Change							2021			Change		% Change
Operating Revenue	Operating Revenue												Operating Revenue
Commercial & Specialty Business	Commercial & Specialty Business	$	9,491		$	9,361		$	130	1.4	%		Commercial & Specialty Business	$	10,269		$	9,491		$	778	8.2	%
Government Business	Government Business	19,283			17,466			1,817		10.4	%		Government Business	23,758			19,283			4,475		23.2	%
IngenioRx	IngenioRx	5,862			5,197			665		12.8	%		IngenioRx	6,683			5,862			821		14.0	%
Other	Other	2,370			1,027			1,343		130.8	%		Other	3,221			2,370			851		35.9	%
Eliminations	Eliminations	(4,908)			(3,603)			(1,305)		36.2	%		Eliminations	(6,045)			(4,908)			(1,137)		NM
Total operating revenue	Total operating revenue	$	32,098		$	29,448		$	2,650	9.0	%		Total operating revenue	$	37,886		$	32,098		$	5,788	18.0	%

Operating Gain	Operating Gain												Operating Gain
Commercial & Specialty Business	Commercial & Specialty Business	$	1,268		$	1,420		$	(152)	(10.7)	%		Commercial & Specialty Business	$	1,082		$	1,268		$	(186)	(14.7)	%
Government Business	Government Business	478			411			67		16.3	%		Government Business	789			478			311		65.1	%
IngenioRx	IngenioRx	407			349			58		16.6	%		IngenioRx	398			407			(9)		(2.2)	%
Other	Other	8			14			(6)		(42.9)	%		Other	178			8			170		NM

Operating Margin	Operating Margin												Operating Margin
Commercial & Specialty Business	Commercial & Specialty Business	13.4		%	15.2		%			(180) bp			Commercial & Specialty Business	10.5		%	13.4		%			(290) bp
Government Business	Government Business	2.5		%	2.4		%			10 bp			Government Business	3.3		%	2.5		%			80 bp
IngenioRx	IngenioRx	6.9		%	6.7		%			20 bp			IngenioRx	6.0		%	6.9		%			(90) bp

Three Months Ended March 31, ~~2021~~2022 Compared to the Three Months Ended March 31, ~~2020~~2021

Commercial & Specialty Business

Operating revenue increased primarily due to higher premiums in our Commercial risk-based businesses due to increased membership, premium rate increases in our ~~Group~~Commercial risk-based ~~business~~businesses designed to cover medical cost trends and increased ~~membership~~administrative fees in our ~~Individual business. These increases were partially offset by decreases in premiums due to the repeal of the HIP Fee in 2021.~~Commercial fee-based businesses.

Operating gain decreased primarily due to ~~costs associated with~~the net unfavorable effect of COVID-19 ~~including testing~~ and ~~vaccine administration as well as investments~~increased selling, general and administrative costs to support ~~growth. The decrease in operating gain was~~growth and innovation. These impacts were partially offset by ~~lower non-COVID-19 healthcare utilization~~positive contribution from the growth in our risk-based and ~~the impact of one less calendar day compared to the first quarter of 2020.~~fee-based membership.

Government Business

Operating revenue increased primarily ~~due to~~as a result of higher premium revenue due mainly to organic membership growth in our Medicaid business ~~driven by~~primarily resulting from the continued temporary suspension of eligibility recertification ~~efforts~~ during the COVID-19 pandemic, which we expect will remain suspended at least through the end of 2021. Acquisitions and new expansions, as well as membership growth and rate increases, in our Medicare business also contributedpandemic. Other contributors to the operating revenue ~~increase. These~~increase were the acquisition of MMM in the second quarter of 2021, the acquisition of Ohio Medicaid members in the first quarter of 2022 through the purchase of a Medicaid contract and the retroactive reinstatement of a Medicaid directed payment program. Membership increases ~~were partially offset by a decline in premium revenue associated with the repeal of the HIP Fee in 2021, as well as certain retroactive~~and rate ~~adjustments and experience-rated refunds~~increases designed to cover medical cost trends in our ~~Medicaid~~Medicare Advantage business ~~and lower risk~~also increased premium revenue.

~~-47-~~

The increase in operating gain was primarily driven by the acquisition of MMM in the second quarter of 2021, organic membership growth in our Medicaid ~~membership~~business resulting from the continued temporary suspension of eligibility recertification during the COVID-19 pandemic, improved risk revenue in Medicare and ~~the impact~~favorable out of ~~one less calendar day compared to the first quarter of 2020. The increase was~~period adjustments in our Medicaid businesses. These increases were partially offset by increased selling, general and administrative costs ~~associated with COVID-19, net of lower non-COVID-19 healthcare utilization, experience-rated refunds in our Medicaid business and lower risk revenue.~~to support growth.

-45-

IngenioRx

Operating revenue increased as a result of higher ~~drug spend from IngenioRx customers including spend relating to increased Medicaid membership within our Government Business segment.~~

~~The increase in operating gain was primarily~~prescription volume, driven by ~~an out of period adjustment and~~ growth in integrated medical and pharmacy members in ~~2021.~~2022.

The decrease in operating gain was primarily driven by the non-recurrence of a favorable out of period adjustment recorded in the first quarter of 2021, partially offset by the impact of higher prescription volume resulting from growth in integrated medical and pharmacy members.

Other

Operating revenue increased primarily due to higher ~~administrative fees and other~~ revenue for expanded services performed by our Diversified Business Group for our Commercial & Specialty Business segment in 2022. In addition, results in 2022 include revenue from myNEXUS, which was acquired in the second quarter of 2021.

Operating gain increased primarily due to improved performance in our Diversified Business Group’s affiliated and ~~Government Business segments, as well as our~~unaffiliated earnings and the acquisition of ~~Beacon in February 2020.~~

myNEXUS. The ~~decrease~~increase in operating gain was further driven by ~~an increase in~~lower unallocated corporate expenses ~~partially offset by growth~~ in ~~our Diversified Business Group.~~2022.

Critical Accounting Policies and Estimates

We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income taxes, goodwill and other intangible assets, investments and retirement benefits. Our accounting policies related to these items are discussed in our ~~2020~~2021 Annual Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,” to our audited consolidated financial statements as of and for the year ended December 31, ~~2020,~~2021, as well as in the “Critical Accounting Policies and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” As of March 31, ~~2021,~~2022, our critical accounting policies and estimates have not changed from those described in our ~~2020~~2021 Annual Report on Form 10-K.

Medical Claims Payable

The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. Our accounting policies related to medical claims payable are discussed in the references cited above. As of March 31, ~~2021,~~2022, our critical accounting policies and estimates related to medical claims payable have not changed from those described in our ~~2020~~2021 Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical claims payable for the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, see Note 9, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

~~-48-~~-46-

The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, which are the trend and completion factors. These two key assumptions can be influenced by utilization levels, unit costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, claim submission patterns and operational changes resulting from business combinations. The impact from COVID-19 on healthcare utilization and medical claims submission patterns continues to provide increased estimation uncertainty on our incurred but not reported liability at March 31, 2022.


		Favorable Developments by Changes in Key Assumptions					Favorable Developments by Changes in Key Assumptions
		Three Months Ended March 31					Three Months Ended March 31
		2021		2020			2022		2021
Assumed trend factors	Assumed trend factors	$	998	$	510	Assumed trend factors	$	880	$	998
Assumed completion factors	Assumed completion factors	490		190		Assumed completion factors	53		490
Total	Total	$	1,488	$	700	Total	$	933	$	1,488

The favorable development recognized in the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 resulted primarily from trend factors in late ~~2020~~2021 and late ~~2019,~~2020, respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter ~~parts~~part of 2020 ~~and 2019~~ developing faster than expected also contributed to the ~~favorability.~~favorable development for the three months ended March 31, 2021.

The ratio of current year medical claims paid as a percent of current year net medical claims incurred was ~~62.1%~~61.0% and ~~64.7%~~62.1% for the three months ended March 31, ~~2021~~2022 and ~~2020,~~2021, respectively. This ratio serves as an indicator of claims processing speed whereby claims ~~were processed at a similar speed~~payments slowed down slightly during the three months ended March 31, ~~2021~~2022 as compared to the three months ended March 31, ~~2020.~~2021. This was driven by the strengthening of incurred but not reported claims, within our medical claims payable, to account for an increase in overall payment cycle time.

We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims payable less prior year redundancies in the current period in order to demonstrate the development of ~~the~~ prior year reserves. For the three months ended March 31, 2022, this metric was 7.6%, largely driven by favorable trend factor development at the end of 2021. For the three months ended March 31, 2021, this metric was 15.5%, largely driven by favorable trend factor development at the end of 2020 as well as favorable completion factor development from ~~2019 and~~ 2020. ~~For the three months ended March 31, 2020, this metric was 8.8%, largely driven by favorable trend factor development at the end of 2019.~~

We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred medical claims to indicate the percentage of redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our prior year estimate of incurred medical claims and the consistency in our methodology. For the three months ended March 31, 2022, this metric was 0.9%, which was calculated using the redundancy of $933. For the three months ended March 31, 2021, ~~this~~the comparable metric was 1.8%, which was calculated using the redundancy of $1,488. ~~For the three months ended March 31, 2020, the comparable metric was 0.9%, which was calculated using the redundancy of $700.~~ We believe these metrics demonstrate an appropriate level of reserve conservatism.

~~Investments~~

The COVID-19 pandemic and efforts to prevent its spread have significantly impacted the global economy, causing market instability and declines in the fair value of our holdings of fixed maturity securities in the energy sector and consumer-driven industries such as travel, entertainment and retail. While the markets have stabilized since the onset of the COVID-19 pandemic, the extent and length of the recovery remain uncertain. Further, the energy sector and consumer-driven industries remain distressed. Given the market uncertainty, there is a risk that our investments that have declined may not recover in future periods.

New Accounting Pronouncements

For information regarding new accounting pronouncements that were adopted and new accounting pronouncements that were issued during the three months ended March 31, ~~2021,~~2022, see the “Recently Adopted Accounting Guidance” and “Recent Accounting Guidance Not Yet Adopted” sections of Note 2, “Basis of Presentation and Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

~~-49-~~

Liquidity and Capital Resources

Sources and Uses of Capital

Our cash receipts result primarily from premiums, product revenue, administrative fees and other revenue, investment income, proceeds from the sale or maturity of our investment securities, proceeds from borrowings, and proceeds from the

-47-

issuance of common stock under our employee stock plans. Cash disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings, acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.

The COVID-19 pandemic and efforts to prevent its spread have significantly impacted the global economy and caused increased volatility in the securities and credit markets. While the full impact of COVID-19 on our business is currently uncertain, it could have a material adverse effect on our financial condition and our liquidity. We intend to continue to monitor market conditions and act in a prudent manner.

For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included in the “Liquidity and Capital Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our ~~2020~~2021 Annual Report on Form 10-K.

For additional information regarding our sources and uses of capital during the three months ended March 31, ~~2021,~~2022, see Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

Liquidity

A summary of our major sources and uses of cash and cash equivalents for the three months ended March 31, ~~2021~~2022 and ~~2020~~2021 is as follows:


		Three Months Ended March 31				2021 vs. 2020			Three Months Ended March 31				2022 vs. 2021
		2021		2020		Change			2022		2021		Change
Sources of Cash:	Sources of Cash:							Sources of Cash:
Net cash provided by operating activities	Net cash provided by operating activities	$	2,505	$	2,515	$	(10)	Net cash provided by operating activities	$	2,541	$	2,505	$	36

Issuances of commercial paper and short- and long-term debt, net of repayments	Issuances of commercial paper and short- and long-term debt, net of repayments	3,212		1,528		1,684		Issuances of commercial paper and short- and long-term debt, net of repayments	211		3,212		(3,001)

Proceeds from issuance of common stock under employee stock plans	Proceeds from issuance of common stock under employee stock plans	89		44		45		Proceeds from issuance of common stock under employee stock plans	76		89		(13)

Other sources of cash, net	Other sources of cash, net	65		—		65		Other sources of cash, net	420		65		355
Total sources of cash	Total sources of cash	5,871		4,087		1,784		Total sources of cash	3,248		5,871		(2,623)
Uses of Cash:	Uses of Cash:							Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and redemptions	Purchases of investments, net of proceeds from sales, maturities, calls and redemptions	(1,330)		(571)		(759)		Purchases of investments, net of proceeds from sales, maturities, calls and redemptions	(794)		(1,330)		536
Purchases of subsidiaries, net of cash acquired	Purchases of subsidiaries, net of cash acquired	(27)		(1,908)		1,881		Purchases of subsidiaries, net of cash acquired	(61)		(27)		(34)
Repurchase and retirement of common stock	Repurchase and retirement of common stock	(447)		(529)		82		Repurchase and retirement of common stock	(545)		(447)		(98)
Purchases of property and equipment	Purchases of property and equipment	(204)		(204)		—		Purchases of property and equipment	(254)		(204)		(50)

Cash dividends	Cash dividends	(277)		(240)		(37)		Cash dividends	(309)		(277)		(32)

Other uses of cash, net		—		(225)		225

Total uses of cash	Total uses of cash	(2,285)		(3,677)		1,392		Total uses of cash	(1,963)		(2,285)		322
Effect of foreign exchange rates on cash and cash equivalents	Effect of foreign exchange rates on cash and cash equivalents	(1)		(2)		1		Effect of foreign exchange rates on cash and cash equivalents	(4)		(1)		(3)
Net increase in cash and cash equivalents	Net increase in cash and cash equivalents	$	3,585	$	408	$	3,177	Net increase in cash and cash equivalents	$	1,281	$	3,585	$	(2,304)

~~Cash~~The increase in cash provided by operating activities was primarily driven by ~~changes in working capital, the impact of membership growth in our Government Business segment and~~ higher net income in ~~2021~~2022, partially offset by the impact of ~~the repeal of the HIP Fee in 2021.~~

~~-50-~~

working capital changes, year-over-year.

Other significant changes in sources or uses of cash year-over-year included ~~a decrease in cash paid for acquisitions, an increase in net~~reduced proceeds ~~received~~ from ~~the issuance of~~commercial paper and short- and long-term debt, ~~and an increase in~~ net of repayments, partially offset by reduced purchases of ~~investments.~~investments, net of proceeds from sales, maturities, calls and redemptions and other sources of cash, net.

Financial Condition

We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity securities of ~~$38,069~~$34,638 at March 31, ~~2021.~~2022. Since December 31, ~~2020,~~2021, total cash, cash equivalents and investments in fixed maturity and equity securities increased by ~~$6,774,~~$978, primarily due to cash generated from operations and net proceeds from the issuance of commercial ~~paper~~paper. The increase was partially offset by cash used for common stock repurchases, dividends paid to shareholders, purchases of property and ~~short- and long-term debt~~equipment and cash ~~generated from operations.~~used for acquisitions.

-48-

Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain undertakings to regulatory authorities, including ~~requirements~~the requirement to maintain certain capital levels in certain of our subsidiaries.

At March 31, ~~2021,~~2022, we held ~~$4,593~~$1,424 of cash, cash equivalents and investments at the parent company, which are available for general corporate use, including investment in our businesses, ~~pending~~ acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and interest payments.

~~Debt~~

Periodically, we access capital markets and issue debt (“Notes”) for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more information on our debt, including redemptions and issuances, see Note 10, “Debt,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our consolidated balance sheets included in Part I, Item 1 of this Form 10-Q. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders’ equity. Total debt is the sum of short-term borrowings, current portion of long-term debt and long-term debt, less current ~~portion and lease liabilities.~~portion. We believe our debt-to-capital ratio assists investors and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated debt-to-capital ratio was ~~41.6%~~39.2% and ~~38.7%~~38.9% as of March 31, ~~2021~~2022 and December 31, ~~2020,~~2021, respectively. ~~The increase in our consolidated debt-to-capital ratio was primarily due to the debt issued in our March bond offering to fund our pending acquisitions and refinance an upcoming debt maturity.~~

Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.

~~Future Sources and Uses of Liquidity~~

We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. The 5-Year Facility provides credit up to $2,500 and matures in June 2024. We also have a 364-day senior revolving credit facility (“364-Day Facility”) with a group of lenders for general corporate purposes, which provides for credit in the amount of $1,000 and matures in June 2021. Our ability to borrow under these credit facilities is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the applicable credit agreement. As of March 31, 2021, our debt-to-capital ratio, as defined and calculated under the credit facilities, was 40.7%. We do not believe the restrictions contained in any of our credit facility covenants materially affect our financial or operating flexibility. As of March 31, 2021, we were in compliance with all of the debt covenants under these credit facilities. There were no amounts outstanding under the 364-Day Facility at any time during the three months ended March 31, 2021 or the year ended December 31, 2020. At March 31, 2021 and December 31, 2020, there were no amounts outstanding under our 5-Year Facility.

~~-51-~~

We have an authorized commercial paper program of up to $3,500, the proceeds of which may be used for general corporate purposes. Should commercial paper issuance become unavailable, we intend to use a combination of cash on hand and/or our senior revolving credit facilities, which provide for combined credit up to $3,500, to redeem any outstanding commercial paper upon maturity. While there is no assurance in the current economic environment, we believe the lenders participating in our senior credit facilities, if market conditions allow, will be willing to provide financing in accordance with their legal obligations. At March 31, 2021, there were no amounts outstanding under our commercial paper program.Capital Resources

We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited amount of any combination of debt or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries, the financing of possible acquisitions or business ~~expansions~~expansions.

We have a senior revolving credit facility (the “5-Year Facility”) with a group of lenders for general corporate purposes. In April 2022, we amended and restated the credit agreement for the 5-Year Facility to, among other things, extend the maturity date of the 5-Year Facility from June 2024 to April 2027 and increase the amount of credit available under the 5-Year Facility from $2,500 to $4,000. Also in April 2022, concurrently with the amendment and restatement of the 5-Year Facility, we terminated our 364-day senior revolving credit facility that provided for credit in the amount of $1,000, which was scheduled to mature in June 2022 (the “2021 364-Day Facility” and together with the 5-Year Facility, the “Credit Facilities”). In June 2021, we terminated our 364-day senior revolving credit facility (the “prior 364-Day Facility”), which was scheduled to mature in June 2021, and entered into the 2021 364-Day Facility with a group of lenders for general corporate purposes. Our ability to borrow under the 5-Year Facility is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital ratio of not more than 60%, subject to increase in certain circumstances set forth in the credit agreement for the 5-Year Facility. We do not believe the restrictions contained in our 5-Year Credit Facility covenants materially affect our financial or operating flexibility. As of March 31, 2022, we were in compliance with all of the ~~repurchase~~debt covenants under the Credit Facilities.

Through certain subsidiaries, we have entered into multiple 364-day lines of ~~shares~~credit (the “Subsidiary Credit Facilities”) with separate lenders for general corporate purposes. The Subsidiary Credit Facilities provide combined credit up to $200.

-49-

Our ability to borrow under the Subsidiary Credit Facilities is subject to compliance with certain covenants. At March 31, 2022 and December 31, 2021, we had no outstanding borrowings under the Subsidiary Credit Facilities.

We have a $3,500 commercial paper program, the proceeds of which may be used for general corporate purposes. Should commercial paper issuance become unavailable, we have the ability to use a combination of cash on hand and/or our ~~common stock.~~5-Year Facility, which provides for credit in the amount of $4,000, to redeem any outstanding commercial paper upon maturity.

We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati, the Federal Home Loan Bank of Atlanta and the Federal Home Loan Bank of New York, collectively (the “FHLBs”). As a member, we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We had $275 of outstanding short-term borrowings from the FHLBs at March 31, 2022 and December 31, 2021.

While there is no assurance in the current economic environment, we believe the lenders participating in our credit facilities, if market conditions allow, would be willing to provide financing in accordance with their legal obligations. At March 31, 2022, we had $525 outstanding under our commercial paper program.

For additional information regarding our sources and uses of capital at March 31, ~~2021,~~2022, see Note 5, “Investments,” Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock – Use of Capital – Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

~~Risk-Based Capital~~

~~Our~~In addition to regulations regarding the timing and amount of dividends, our regulated subsidiaries’ states of domicile have statutory risk-based capital (“RBC”) requirements for health and other insurance companies and health maintenance organizations largely based on the National Association of Insurance Commissioners (“NAIC”) Risk-Based Capital (RBC) for ~~Insurers~~Health Organizations Model Act (the ~~"RBC~~“RBC Model ~~Act"~~Act”). These RBC requirements are intended to measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the formula for calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an individual insurance company’s business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of December 31, ~~2020,~~2021, which was the most recent date for which reporting was required, were in excess of all applicable mandatory RBC requirements. In addition to exceeding ~~the~~these RBC requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net ~~equity~~worth requirements applicable to certain of our California subsidiaries.

For additional information, see Note 22, “Statutory Information,” in our audited consolidated financial statements as of and for the year ended December 31, ~~2020~~2021 included in our ~~2020~~2021 Annual Report on Form 10-K.

~~Contractual Obligations~~Future Sources and ~~Commitments~~Uses of Liquidity

We believe that funds from cash on hand, future operating cash ~~flows, cash and~~receipts, investments and funds available under our ~~5-year~~commercial paper program, our 5-Year Facility, our Subsidiary Credit Facilities and ~~364-day senior revolving credit facilities and/or from public or private financing sources~~the FHLBs will be ~~sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.~~adequate to fund our expected cash disbursements over the next twelve months.

There have been no material changes to our ~~Contractual Obligations and Commitments disclosure~~long-term liquidity requirements as disclosed in our ~~2020~~2021 Annual Report on Form ~~10-K other than an increase in our borrowings.~~10-K. For additional ~~information~~updates regarding our estimated ~~contractual obligations and commitments,~~long-term liquidity requirements, see Note 6, “Derivative Financial Instruments,” Note 10, “Debt,” and the “Other Contingencies” and “Contractual Obligations and Commitments” sections of Note 11 “Commitments and Contingencies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q. We believe that funds from future operating cash flows, cash and investments and funds available under our 5-Year Facility and/or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic transactions.

~~-52-~~-50-

FORWARD-LOOKING STATEMENTS

This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium rates, including regulatory approval for and implementation of such rates; the impact of federal, state and ~~state~~international law and regulation, including ongoing changes in the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as ~~amended (collectively, the “ACA”), and the ultimate outcome of legal challenges to the ACA;~~amended; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; reduced enrollment; the impact of a cyber-attack or other cyber security breach resulting in unauthorized disclosure of member or employee sensitive or confidential information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, ~~(including the ultimate outcome of litigation between Cigna Corporation and us related to the merger agreement between the parties),~~ government investigations, audits or reviews; risks and uncertainties related to our pharmacy benefit management (“PBM”) business, including non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.; medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated with mergers, acquisitions, joint ventures and strategic alliances; changes in ~~U.S.~~ tax laws; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; ~~the impact of international laws and regulations;~~ intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations.

~~-53-~~-51-

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our ~~2020~~2021 Annual Report on Form 10-K. There have been no material changes to any of these risks since December 31, ~~2020.~~2021.

ITEM 4. CONTROLS AND PROCEDURES

We carried out an evaluation as of March 31, ~~2021,~~2022, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.

There have been no changes in our internal control over financial reporting that occurred during the three months ended March 31, ~~2021~~2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

For information regarding legal proceedings at March 31, ~~2021,~~2022, see the “Litigation and Regulatory Proceedings,” and “Other Contingencies” sections of Note 11, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q, which information is incorporated herein by reference.

ITEM 1A. RISK FACTORS

There have been no material changes to the risk factors disclosed in our ~~2020~~2021 Annual Report on Form 10-K.

~~-54-~~-52-

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

The following table presents information related to our repurchases of common stock for the periods indicated:

Period
Total Number
of Shares
Purchased1
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)
January 1, 2021 to January 31, 2021 496,541 $ 319.59 493,200 $ 5,935
February 1, 2021 to February 28, 2021 528,311 295.23 527,734 5,779
March 1, 2021 to March 31, 2021 679,367 327.81 393,985 5,645
1,704,219 1,414,919


Period	Total Number of Shares Purchased1	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Programs2	Approximate Dollar Value of Shares that May Yet Be Purchased Under the Programs
(in millions, except share and per share data)
January 1, 2022 to January 31, 2022	469,833	$	446.37	467,595	$	3,983
February 1, 2022 to February 28, 2022	351,000	447.83		349,528	3,827
March 1, 2022 to March 31, 2022	570,779	462.60		386,216	3,647
	1,391,612			1,203,339

1 Total number of shares purchased includes ~~289,300~~188,273 shares delivered to or withheld by us in connection with employee payroll tax withholding upon the exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the consolidated statements of shareholders’ equity are shown net of these shares purchased.

2 Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of Directors evaluates periodically. During the three months ended March 31, ~~2021,~~2022, we repurchased ~~1,414,919~~1,203,339 shares at a total cost of ~~$447~~$545 under the program, including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The most recent authorized increase to the program was $5,000 on January 26, 2021 by our Audit Committee, pursuant to authorization granted by the Board of Directors. No duration has been placed on our common stock repurchase program, and we reserve the right to discontinue the program at any time.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

~~-55-~~-53-

ITEM 6. EXHIBITS

Exhibit

Number

Exhibit

3.1

Amended and Restated Articles of Incorporation of the Company, as amended and restated effective May 15, 2019, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 15, 2019.

3.2

Bylaws of the Company, as amended effective September 30, 2020, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 6, 2020.

~~4.6~~

~~(l)~~

~~Form of the 0.450% Notes due 2023, incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on March 17, 2021.~~

~~(m)~~

~~Form of the 1.500% Notes due 2026, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on March 17, 2021.~~

~~(n)~~

~~Form of the 2.550% Notes due 2031, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on March 17, 2021.~~

~~(o)~~

~~Form of the 3.600% Notes due 2051, incorporated by reference to Exhibit 4.4 to the Company’s Current Report on Form 8-K filed on March 17, 2021.~~

4.7

Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the rights of holders of long-term debt of the Company or its subsidiaries.

10.2

~~(m)~~(l)

Form of Incentive Compensation Plan Nonqualified Stock Option Award Agreement for ~~2021.~~2022.

(m)

Form of Incentive Compensation Plan Restricted Stock Unit Award Agreement for 2022.

(n)

Form of Incentive Compensation Plan ~~Restricted Stock Unit Award Agreement for 2021.~~

~~(o)~~

~~Form of Incentive Compensation Plan~~ Performance Stock Unit Award Agreement for ~~2021.~~2022.

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101

The following material from Anthem, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, ~~2021,~~2022, formatted in Inline XBRL (Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of Shareholders’ Equity; and (vi) Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

104

Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.

~~Indicates management contracts or compensatory plans or arrangements.~~

~~-56-~~-54-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	ANTHEM, INC. Registrant



April ~~21, 2021~~20, 2022	By:	/S/ JOHN E. GALLINA
		John E. Gallina Executive Vice President and Chief Financial Officer (Duly Authorized Officer and Principal Financial Officer)


April ~~21, 2021~~20, 2022	By:	/S/ RONALD W. PENCZEK
		Ronald W. Penczek ~~Senior Vice President and~~ Chief Accounting Officer and Controller (Principal Accounting Officer)

~~-57-~~-55-


	March 31, 2021		December 31, 2020
(In millions, except share data)	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	9,326	$	5,741
Fixed maturity securities (amortized cost of $23,808 and $22,222; allowance for credit losses of $8 and $7)	24,555		23,433
Equity securities	3,630		1,559


Premium receivables	6,111		5,279
Self-funded receivables	3,109		2,849
Other receivables	3,071		2,830


Other current assets	4,693		4,060
Total current assets	54,495		45,751
Long-term investments:
Fixed maturity securities (amortized cost of $537 and $532; allowance for credit losses of $0 and $0)	558		562

Other invested assets	4,474		4,285
Property and equipment, net	3,533		3,483
Goodwill	21,708		21,691
Other intangible assets	9,352		9,405
Other noncurrent assets	1,563		1,438
Total assets	$	95,683	$	86,615

Liabilities and equity
Liabilities
Current liabilities:

Medical claims payable	$	12,347	$	11,359

Other policyholder liabilities	5,075		4,590

Unearned income	1,139		1,259
Accounts payable and accrued expenses	5,329		5,493




Current portion of long-term debt	700		700
Other current liabilities	10,159		6,052
Total current liabilities	34,749		29,453
Long-term debt, less current portion	22,534		19,335
Reserves for future policy benefits	776		794
Deferred tax liabilities, net	1,961		2,019
Other noncurrent liabilities	1,745		1,815
Total liabilities	61,765		53,416

Commitments and contingencies – Note 11	0		0

Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none	0		0
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding – 244,938,635 and 245,401,430	2		3
Additional paid-in capital	9,253		9,244
Retained earnings	24,793		23,802
Accumulated other comprehensive (loss) income	(195)		150
Total shareholders’ equity	33,853		33,199
Noncontrolling interests	65		0
Total equity	33,918		33,199
Total liabilities and equity	$	95,683	$	86,615